




Form PTO-1390* (REV. 11-2000)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER 9286-7	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371				U.S. APPLICATION NO. (If known, see 37 CFR 1.5) 10/019902	
INTERNATIONAL APPLICATION NO. PCT/EP00/06139		INTERNATIONAL FILING DATE 30 June 2000		PRIORITY DATE CLAIMED 30 June 1999	
TITLE OF INVENTION COMPOUNDS THAT ASSOCIATE ON THE INTERMOLECULAR LEVEL AND AGGREGATE BODIES THAT CONTAIN THEM					
APPLICANT(S) FOR DO/EO/US Nikolai Vladimirovich BOVIN; Alexander Borisovich TUSIKOV; Alexander Alexandrovich CHINAREV, Maria Alexandravona DICUSAR; Alexandra Sergeevna GAMBARIAN; Valentina Petrovna MARININA					
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:					
<ol style="list-style-type: none"> 1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 3. <input type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below. 4. <input type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (Article 31). 5. <input type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) <ol style="list-style-type: none"> a. <input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau). b. <input checked="" type="checkbox"/> has been communicated by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). 6. <input checked="" type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). <ol style="list-style-type: none"> a. <input checked="" type="checkbox"/> is attached hereto. b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4) 7. <input type="checkbox"/> Amendments to the claims of the International Application Under PCT Article 19 (35 U.S.C. 371(c)(3)) <ol style="list-style-type: none"> a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> have been communicated by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report Under PCT Article 36 (35 U.S.C. 371(c)(5)). 					
Items 11 to 20 below concern document(s) or information included:					
<ol style="list-style-type: none"> 11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. <input checked="" type="checkbox"/> A FIRST preliminary amendment. 14. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. 15. <input type="checkbox"/> A substitute specification. 16. <input type="checkbox"/> A change of power of attorney and/or address letter. 17. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825. 18. <input checked="" type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4). 19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4) 20. <input type="checkbox"/> Other items or information: 					

531 Rec'd PCT/F 21 DEC 2001

10/019902

U.S. APPLICATION NO. (if known) see 37 CFR 1.55				INTERNATIONAL APPLICATION NO. PCT/EP00/06139		ATTORNEY DOCKET NO. 9286-7			
21. <input checked="" type="checkbox"/> The following fees are submitted						CALCULATIONS		PTO USE ONLY	
BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5)):									
Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO.....						\$1040.00			
International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO.....						\$890.00			
International preliminary examination fee 37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO.....						\$740.00			
International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4).....						\$710.00			
International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4).....						\$100.00			
ENTER APPROPRIATE BASE FEE AMOUNT =						\$890.00			
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).						\$			
CLAIMS		NUMBER FILED		NUMBER EXTRA		RATE		\$	
Total claims		23 - 20 =		3		x \$18.00		\$54.00	
Independent Claims		10 - 3 =		7		x \$84.00		\$588.00	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)						+ \$280.00		\$	
TOTAL OF ABOVE CALCULATIONS =						\$			
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2						\$			
SUBTOTAL =						\$			
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).						\$			
TOTAL NATIONAL FEE =						\$			
Fee for Recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +						\$			
TOTAL FEES ENCLOSED =						\$1,532.00			
						Amount to be refunded:		\$	
						charged:		\$	
a. <input type="checkbox"/> A check in the amount of \$_____ to cover the above fees is enclosed.									
b. <input checked="" type="checkbox"/> Please charge my Deposit Account No. 50-0220 in the amount of \$1,532.00 to cover the above fees. A duplicate copy of this sheet is enclosed.									
c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 50-0220. A duplicate copy of this sheet is enclosed.									
d. <input type="checkbox"/> Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.									
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.									
SEND ALL CORRESPONDENCE TO:									
 20792 PATENT TRADEMARK OFFICE				 Jarett K. Abramson, #47,376 Date: December 21, 2001					
CERTIFICATE OF EXPRESS MAILING Express Mail Label No. EL 920742783 US Date of Deposit: December 21, 2001 I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to: BOX PCT, Attn. DO/EO/US, Commissioner for Patents, Washington, DC 20231.  Susan E. Freedman, December 21, 2001									

10/019902

531 Rec'd PCT/PTC 21 DEC 2001

Attorney Docket No. 9286-7

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Nikolai Vladimirovich Bovin et al.

Serial No.: To Be Assigned

Filed: Concurrently Herewith

For: COMPOUNDS THAT ASSOCIATE ON THE INTERMOLECULAR LEVEL AND
AGGREGATE BODIES THAT CONTAIN THEM

December 21, 2001

Box PCT
Commissioner for Patents
Washington, DC 20231

Attn: DO/EO/US

PRELIMINARY AMENDMENT

Sir:

Prior to the examination of the above application and calculation of claim fees, please amend the above-identified application as indicated below. Attached hereto, is a marked-up version of the changes made to the specification and claims by the current amendment.

In the Specification:


On page 1, on a line below the Title of the Invention, please insert the following:

Cross-Reference to Related Applications

The present application is a U.S. national phase application of PCT International Application No. PCT/EP00/06139 (published under PCT Article 21(2) in German), filed on June 30, 2000, which claims priority to German Patent Application 199 30 177.8, filed June 30, 1999, the disclosures of which are incorporated herein by reference in their entirety.

In the Claims:

1. (Amended) A compound of the general formula (I)



wherein

X is an m-valent unit and

In re: Nikolai Vladimirovich Bovin et al.

Serial No.: To Be Assigned

Filed: Concurrently Herewith

Page 2 of 30

B are identical or different and denote K-R,

wherein

K is a bond or is $A^1-(A^2-A^3)_k-sp$, wherein

A^1 is $(CH_2)_tY(CH_2)_u$, wherein

Y is $>C=O$, $>NH$, $-O-$, $-S-$ or a bond,

t is an integer from 0 to 6 and

u is an integer from 0 to 6,

A^2 is $-NHCO-$, $-CONH-$, $-OCONH-$ or $SCONH-$, or is $-CO-$,

A^3 is $(CH_2)_r$, $O(CH_2)_r$, $NH(CH_2)_r$, $S(CH_2)_r$ or $-(CHQ)-$, wherein

r is an integer from 1 to 6 and

Q is a substituted or unsubstituted alkyl or aryl group,

sp is a divalent spacer or a bond, and

k is an integer from 5 to 100, and

R is hydrogen; a ligand suitable for specific bonding to a receptor;

a marker molecule; or a catalytically active group; and

m is at least 2,

with the proviso that

- (1) in the compound at least one R is not hydrogen,
- (2) there are at least two K that are not a bond, and
- (3) X, B and m are so selected that an intermolecular association of the K in liquid phase by the formation of hydrogen bonds is possible, with formation of aggregates that present on the surface a plurality of R that are not hydrogen, and
- (4) the molar mass of the fragment $X(K)_m$ is less than 20,000.

2. (Amended) A compound according to claim 1, wherein the molar mass of the fragment $X(K)_m$ is less than 4,000.

3. (Amended) A compound according to claim 1, wherein

m is an integer from 2 to 4, and

X is CH_{4-m} , NH_{3-m} , N^+H_{4-m} , $>P-$ (when $m = 3$), $>P^+<$ (when $m = 4$), $>B-$ (when $m = 3$), a linear atom group C_2H_{6-m} , $>CH(CH_2)_zCH<$, $>C=C<$, $>N-N<$, $>N(CH_2)_zN<$ wherein $z = 2 - 6$, when $m = 4$), a carbocyclic atom group C_6H_6 .

In re: Nikolai Vladimirovich Bovin et al.
 Serial No.: To Be Assigned
 Filed: Concurrently Herewith
 Page 3 of 30

m , C_6H_{12-m} , or a heterocyclic atom group C_3N_3 (when $m = 3$), C_4N_2 (when $m = 4$).

4. (Amended) A compound according to claim 1, wherein there are at least 3 K.
5. (Amended) A compound according to claim 1, wherein at least two R are not hydrogen.
6. (Amended) A compound according to claim 1, wherein at least three R are not hydrogen.
7. (Amended) A compound according to claim 1, wherein the ligand R is a mono- or oligo-saccharide, a peptide, a mono- or oligo-nucleotide or a nucleic base and their derivatives and mimetics.
8. (Amended) A compound according to claim 7, wherein the saccharide R is sialic acid, sialyl lactose, sialyl lactosamine, lactose, mannose, $Gal\alpha 1-3Gal$, $Gal\alpha 1-3(Fuc\alpha 1-2)Gal$, $GalNAc\alpha 1-3(Fuc\alpha 1-2)Gal$, $Neu5Ac\alpha 2-6GalNAc$, $SiaLe^A$, $SiaLe^X$, HSO_3Le^A , HSO_3Le^X , $Gal\alpha 1-3Gal\beta 1-4GlcNAc$, $Gal\alpha 1-3Gal\beta 1-4Glc$, $HSO_3GlcA\beta 1-3Gal\beta 1-4GlcNAc$, N-acetyl-lactosamine or polylactosamine, or wherein the saccharide is sialic acid benzyl glycoside, $HSO_3GlcA\beta 1-3Gal$, $HSO_3GlcA\beta 1-3Gal\beta 1-4GlcNAc\beta 1-3Gal\beta 1-4Glc$, $GalNAc\alpha$, $GalNAc\alpha 1-3(Fuc\alpha 1-2)Gal\beta 1-4GlcNAc$, $Gal\alpha 1-3(Fuc\alpha 1-2)Gal\beta 1-4GlcNAc$, $HSO_3(Sia)Le^X$, $HSO_3(Sia)Le^A$, Le^Y , $GlcNAc\beta 1-6(GlcNAc\beta 1-3)Gal\beta 1-4Glc$, $GalNAc\beta 1-4(Neu5Ac\alpha 2-3)Gal\beta 1-4Glc$, mannose-6-phosphate, $GalNAc\beta 1-4GlcNAc$, oligo-sialic acid, N-glycolylneuraminic acid, $Gal\alpha 1-4Gal\beta 1-4Glc$, $Gal\alpha 1-4Gal\beta 1-4GlcNAc$.

9. (Amended) A compound according to claim 1, wherein

- m is an integer from 2 to 4,
- X is CH_{4-m} ,
- A^1 is CH_2 ,
- A^2 is $NHCO$,

A^3 is CH_2 ,
 k is 8,
 sp is $(CH_2)_3CONHCH_2CONHC_6H_4-4-CH_2O-$ and
 R is Neu5Ac α 2-6Gal β 1-4GlcNAc.

10. (Amended) An aggregate of the general formula (II):



wherein

$X(B)_m$ may be identical or different and denote a compound of the general formula (I),



wherein

X is an m -valent unit and

B are identical or different and denote $K-R$,

wherein

K is a bond or is $A^1-(A^2-A^3)_k-sp$, wherein

A^1 is $(CH_2)_tY(CH_2)_u$, wherein

Y is $>C=O$, $>NH$, $-O-$, $-S-$ or a bond,

t is an integer from 0 to 6 and

u is an integer from 0 to 6,

A^2 is $-NHCO-$, $-CONH-$, $-OCONH-$ or $SCONH-$, or is $-CO-$,

A^3 is $(CH_2)_r$, $O(CH_2)_r$, $NH(CH_2)_r$, $S(CH_2)_r$ or $-(CHQ)-$, wherein

r is an integer from 1 to 6 and

Q is a substituted or unsubstituted alkyl or aryl group,

sp is a divalent spacer or a bond, and

k is an integer from 5 to 100, and

R is hydrogen; a ligand suitable for specific bonding to a receptor;
 a marker molecule; or a catalytically active group; and

m is at least 2,

with the proviso that

- (1) in the compound at least one R is not hydrogen,
- (2) there are at least two K that are not a bond, and

In re: Nikolai Vladimirovich Bovin et al.
 Serial No.: To Be Assigned
 Filed: Concurrently Herewith
 Page 5 of 30

- (3) X, B and m are so selected that an intermolecular association of the K in liquid phase by the formation of hydrogen bonds is possible, with formation of aggregates that present on the surface a plurality of R that are not hydrogen, and
- (4) the molar mass of the fragment $X(K)_m$ is less than 20,000, and n is from 2 to 100,000, and wherein $X(B)_m$ are non-covalently bonded.

11. (Amended) An aggregate according to claim 10 having a leaf-like, linear, cyclic, polycyclic, polyhedral, spherical or dendritic structure.

12. (Amended) An aggregate according to claim 10 of two or more different compounds comprising a compound of the general formula (I)



wherein

X is an m-valent unit and

B are identical or different and denote K-R,

wherein

K is a bond or is $A^1-(A^2-A^3)_k\text{-sp}$, wherein

A^1 is $(CH_2)_tY(CH_2)_u$, wherein

Y is $>C=O$, $>NH$, $-O-$, $-S-$ or a bond,

t is an integer from 0 to 6 and

u is an integer from 0 to 6,

A^2 is $-NHCO-$, $-CONH-$, $-OCONH-$ or $SCONH-$, or is $-CO-$,

A^3 is $(CH_2)_r$, $O(CH_2)_r$, $NH(CH_2)_r$, $S(CH_2)_r$ or $-(CHQ)-$, wherein

r is an integer from 1 to 6 and

Q is a substituted or unsubstituted alkyl or aryl group,

sp is a divalent spacer or a bond, and

k is an integer from 5 to 100, and

R is hydrogen; a ligand suitable for specific bonding to a receptor; a marker molecule; or a catalytically active group; and

m is at least 2,

with the proviso that

In re: Nikolai Vladimirovich Bovin et al.
 Serial No.: To Be Assigned
 Filed: Concurrently Herewith
 Page 6 of 30

- (1) in the compound at least one R is not hydrogen,
- (2) there are at least two K that are not a bond, and
- (3) X, B and m are so selected that an intermolecular association of the K in liquid phase by the formation of hydrogen bonds is possible, with formation of aggregates that present on the surface a plurality of R that are not hydrogen, and
- (4) the molar mass of the fragment $X(K)_m$ is less than 20,000.

Claim 13 has been canceled.

14. (Amended) A method according to claim 27, further comprising adding a concentrated salt solution, changing the pH or the temperature, or adding organic solvents.

15. (Amended) A method for changing the structure of an aggregate of the general formula (II)



wherein

$X(B)_m$ may be identical or different and denote a compound of the general formula (I),



wherein

X is an m-valent unit and

B are identical or different and denote K-R,

wherein

K is a bond or is $A^1-(A^2-A^3)_k$ -sp, wherein

A^1 is $(CH_2)_tY(CH_2)_u$, wherein

Y is $>C=O$, $>NH$, $-O-$, $-S-$ or a bond,

t is an integer from 0 to 6 and

u is an integer from 0 to 6,

A^2 is $-NHCO-$, $-CONH-$, $-OCONH-$ or $SCONH-$, or is $-CO-$,

A^3 is $(CH_2)_r$, $O(CH_2)_r$, $NH(CH_2)_r$, $S(CH_2)_r$ or $-(CHQ)-$, wherein

r is an integer from 1 to 6 and

Q is a substituted or unsubstituted alkyl or aryl group,

sp is a divalent spacer or a bond, and

R is hydrogen; a ligand suitable for specific bonding to a receptor; a marker molecule; or a catalytically active group; and

- (1) in the compound at least one R is not hydrogen,
- (2) there are at least two K that are not a bond, and
- (3) X, B and m are so selected that an intermolecular association of the K in liquid phase by the formation of hydrogen bonds is possible, with formation of aggregates that present on the surface a plurality of R that are not hydrogen, and
- (4) the molar mass of the fragment $X(K)_m$ is less than 20,000, and n is from 2 to 100,000,

and wherein $X(B)_m$ are non-covalently bonded,

further comprising adding a concentrated salt solution, changing the temperature or the pH and/or adding urea, trifluoroethanol or peptides.

16. (Amended) A method according to claim 27 further comprising increasing the specific physiological activities of molecules by incorporating a radical R into a compound of the general formula (I).

Claim 17 has been canceled.

18. (Amended) A method of treating diseases arising from inflammation, viral and bacterial infections, influenza viruses, selectin-mediated inflammatory processes, tumour metastases, or in the neutralisation of antibodies in autoimmune disorders and transplants; said method comprising administering a compound of the general formula (I)



wherein

X is an m-valent unit and

B are identical or different and denote K-R,

wherein

K is a bond or is $A^1-(A^2-A^3)_k$ -sp, wherein

m is at least 2,
with the proviso that

- (1) in the compound at least one R is not hydrogen,
- (2) there are at least two K that are not a bond, and
- (3) X, B and m are so selected that an intermolecular association of the K in liquid phase by the formation of hydrogen bonds is possible, with formation of aggregates that present on the surface a plurality of R that are not hydrogen, and
- (4) the molar mass of the fragment $X(K)_m$ is less than 20,000; or administering into an aggregate of the general formula (II)

$$\{X(B)_m\}_n \quad (II)$$

wherein

X(B)_m may be identical or different and denote a compound of the general formula (I), and

n is from 2 to 100,000,

and wherein X(B)_m are non-covalently bonded.

Claim 19 has been canceled.

20. (Amended) A method according to claim 18 further comprising preparing functionalized molecular surfaces.

Claims 21 and 22 have been canceled.

23. (Amended) A compound of the general formula (III),



wherein

X is an m-valent unit and

B are identical or different and denote K-H,
wherein

K is $\text{A}^1-(\text{A}^2-\text{A}^3)_k\text{-sp}$, wherein

A^1 is $(\text{CH}_2)_t\text{Y}(\text{CH}_2)_u$, wherein

Y is $>\text{C}=\text{O}$, $>\text{NH}$, $-\text{O}-$, $-\text{S}-$ or a bond,

t is an integer from 0 to 6 and

u is an integer from 0 to 6,

A^2 is $-\text{NHCO}-$, $-\text{CONH}-$, $-\text{OCONH}-$ or $\text{SCONH}-$, or is $-\text{CO}-$,

A^3 is $(\text{CH}_2)_r$, $\text{O}(\text{CH}_2)_r$, $\text{NH}(\text{CH}_2)_r$, $\text{S}(\text{CH}_2)_r$ or $-(\text{CHQ})-$, wherein

r is an integer from 1 to 6 and

Q is a substituted or unsubstituted alkyl or aryl group,

sp is a divalent spacer or a bond, and

k is an integer from 5 to 100, and

m is at least 2,

with the proviso that

- (1) X, B and m are so selected that an intermolecular association of the K in liquid phase is possible, especially under aqueous conditions, by the formation of hydrogen bonds, with formation of aggregates, and
- (2) the molar mass of the fragment X(K)_m is less than 20,000, especially less than 4000.

Claim 24 has been canceled.

25. (New) A method of preparing a therapeutic drug comprising:
preparing a compound of the general formula (III),



wherein

X is an m-valent unit and

B are identical or different and denote K-H,

wherein

K is $A^1-(A^2-A^3)_k$ -sp, wherein

A^1 is $(CH_2)_t Y(CH_2)_u$, wherein

Y is $>C=O$, $>NH$, $-O-$, $-S-$ or a bond,

t is an integer from 0 to 6 and

u is an integer from 0 to 6,

A^2 is $-NHCO-$, $-CONH-$, $-OCONH-$ or $SCONH-$, or is $-CO-$,

A^3 is $(CH_2)_r$, $O(CH_2)_r$, $NH(CH_2)_r$, $S(CH_2)_r$ or $-(CHQ)-$, wherein

r is an integer from 1 to 6 and

Q is a substituted or unsubstituted alkyl or aryl group,

sp is a divalent spacer or a bond, and

k is an integer from 5 to 100, and

m is at least 2,

with the proviso that

- (1) X, B and m are so selected that an intermolecular association of the K in liquid phase is possible, especially under aqueous conditions, by the formation of hydrogen bonds, with formation of aggregates, and
- (2) the molar mass of the fragment $X(K)_m$ is less than 20,000, especially less than 4000.

26. (New) A method of treating diseases arising from inflammation, viral and bacterial infections, influenza viruses, selectin-mediated inflammatory processes, tumour metastases, or in the neutralisation of antibodies in autoimmune disorders and transplants; said method comprising administering a compound of the general formula (III),



wherein

X is an m-valent unit and

B are identical or different and denote K-H,
 wherein

K is $A^1-(A^2-A^3)_k\text{-sp}$, wherein

A^1 is $(CH_2)_tY(CH_2)_u$, wherein

Y is $>C=O$, $>NH$, $-O-$, $-S-$ or a bond,

t is an integer from 0 to 6 and

u is an integer from 0 to 6,

A^2 is $-NHCO-$, $-CONH-$, $-OCONH-$ or $SCONH-$, or is $-CO-$,

A^3 is $(CH_2)_r$, $O(CH_2)_r$, $NH(CH_2)_r$, $S(CH_2)_r$ or $-(CHQ)-$, wherein

r is an integer from 1 to 6 and

Q is a substituted or unsubstituted alkyl or aryl group,

sp is a divalent spacer or a bond, and

k is an integer from 5 to 100, and

m is at least 2,

with the proviso that

- (1) X, B and m are so selected that an intermolecular association of the K in liquid phase is possible, especially under aqueous conditions, by the formation of hydrogen bonds, with formation of aggregates, and
- (2) the molar mass of the fragment $X(K)_m$ is less than 20,000, especially less than 4000.

27. (New) A method of preparing an aggregate comprising:
 preparing a compound of the general formula (II)



wherein

$X(B)_m$ may be identical or different and denote a compound of the general formula (I),



X is an m-valent unit and
B are identical or different and denote K-R,
wherein

with the proviso that

- (1) in the compound at least one R is not hydrogen,
 - (2) there are at least two K that are not a bond, and
 - (3) X, B and m are so selected that an intermolecular association of the K in liquid phase by the formation of hydrogen bonds is possible, with formation of aggregates that present on the surface a plurality of R that are not hydrogen, and
 - (4) the molar mass of the fragment $X(K)_m$ is less than 20,000, and
- n is from 2 to 100,000,
- and wherein $X(B)_m$ are non-covalently bonded.

28. (New) A method of preparing a therapeutic drug comprising:
preparing the compound of the general formula (I)



wherein

B are identical or different and denote K-R, wherein

k is an integer from 5 to 100, and

R is hydrogen; a ligand suitable for specific bonding to a receptor; a marker molecule; or a catalytically active group; and

with the proviso that

- (1) in the compound at least one R is not hydrogen,
- (2) there are at least two K that are not a bond, and
- (3) X, B and m are so selected that an intermolecular association of the K in liquid phase by the formation of hydrogen bonds is possible, with formation of aggregates that present on the surface a plurality of R that are not hydrogen, and
- (4) the molar mass of the fragment $X(K)_m$ is less than 20,000; or
preparing the compound of the general formula (II):



X(B)_m may be identical or different and denote a compound of the general formula (I), and

and wherein $X(B)_m$ are non-covalently bonded; and
a pharmaceutically acceptable carrier.

providing a test reagent

$$X(B)_m \quad (I)$$

X is an m-valent unit and

wherein

A¹ is (CH₂)_tY(CH₂)_u, wherein

Y is $>\text{C}=\text{O}$, $>\text{NH}$, $-\text{O}-$, $-\text{S}-$ or a bond,

t is an integer from 0 to 6 and

u is an integer from 0 to 6,

A² is -NHCO-, -CONH-, -OCONH- or SCONH-, or is -CO-,

A³ is (CH₂)_r, O(CH₂)_r, NH(CH₂)_r, S(CH₂)_r or -(CHQ)-, wherein

r is an integer from 1 to 6 and

Q is a substituted or unsubstituted alkyl or aryl group,

sp is a divalent spacer or a bond, and

k is an integer from 5 to 100, and

R is hydrogen; a ligand suitable for specific bonding to a receptor;

a marker molecule; or a catalytically active group; and

with the proviso that

- (1) in the compound at least one R is not hydrogen,
- (2) there are at least two K that are not a bond, and
- (3) X, B and m are so selected that an intermolecular association of the K in liquid phase by the formation of hydrogen bonds is possible, with formation of aggregates that present on the surface a plurality of R that are not hydrogen, and
- (4) the molar mass of the fragment $X(K)_m$ is less than 20,000; or

preparing an aggregate of the general formula (II)

In re: Nikolai Vladimirovich Bovin et al.
 Serial No.: To Be Assigned
 Filed: Concurrently Herewith
 Page 15 of 30



wherein

$X(B)_m$ may be identical or different and denote a compound of the general formula (I), and

n is from 2 to 100,000,

and wherein $X(B)_m$ are non-covalently bonded;


and comparing the test reagent to the compounds of the general formula (I) or (II).

In re: Nikolai Vladimirovich Bovin et al.
Serial No.: To Be Assigned
Filed: Concurrently Herewith
Page 16 of 30

REMARKS

The claims have been amended to better conform with U.S. practice, such as removing multiple dependencies. Applicants respectfully request substantive examination on the merits.

Respectfully submitted,



Jarett K. Abramson
Registration No. 47,376
Attorney for Applicants



20792

PATENT TRADEMARK OFFICE

CERTIFICATE OF EXPRESS MAILING

Express Mail Label No. EL 920742783 US
Date of Deposit: December 21, 2001

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to: BOX PCT, Attn: DO/EQ/US, Commissioner for Patents, Washington, DC 20231.



Susan E. Freedman

Date of Signature. December 21, 2001

VERSION WITH MARKINGS TO SHOW CHANGES MADE

The following is an addendum to the concurrently filed Preliminary Amendment in the above-referenced application. This addendum includes a marked-up version of the changes made to the claims by the present Preliminary Amendment.

In the Claims:

1. (Amended) [Compound] A compound of the general formula (I)



wherein

X is an m-valent unit and

B are identical or different and denote K-R,

wherein

K is a bond or is $A^1-(A^2-A^3)_k\text{-sp}$, wherein

A^1 is $(\text{CH}_2)_t\text{Y}(\text{CH}_2)_u$, wherein

Y is $>\text{C}=\text{O}$, $>\text{NH}$, $-\text{O}-$, $-\text{S}-$ or a bond,

t is an integer from 0 to 6 and

u is an integer from 0 to 6,

A^2 is $-\text{NHCO}-$, $-\text{CONH}-$, $-\text{OCONH}-$ or $\text{SCONH}-$, or is $-\text{CO}-$,

A^3 is $(\text{CH}_2)_r$, $\text{O}(\text{CH}_2)_r$, $\text{NH}(\text{CH}_2)_r$, $\text{S}(\text{CH}_2)_r$ or $-(\text{CHQ})-$, wherein

r is an integer from 1 to 6 and

Q is a substituted or unsubstituted alkyl or aryl group,

sp is a divalent spacer or a bond, and

k is an integer from 5 to 100, and

R is hydrogen; a ligand suitable for specific bonding to a receptor;
a marker molecule; or a catalytically active group; and

m is at least 2,

with the proviso that

- (1) in the compound at least one R is not hydrogen,
- (2) there are at least two K that are not a bond, and

8. (Amended) [Compound] A compound according to claim 7, wherein the saccharide R is sialic acid, sialyl lactose, sialyl lactosamine, lactose, mannose, Gal α 1-3Gal,

9. (Amended) [Compound] A compound according to [any one of claims 1 to 8]
claim 1, wherein

m is an integer from 2 to 4,
X is CH_{4-m},
A¹ is CH₂,
A² is NHCO,
A³ is CH₂,
k is 8,
sp is (CH₂)₃CONHCH₂CONHC₆H₄-4-CH₂O- and
R is Neu5Acα2-6Galβ1-4GlcNAc.

10. (Amended) [Aggregate] An aggregate of the general formula (II):



wherein

X(B)_m may be identical or different and denote a compound of the general formula (I), [as defined in any one of claims 1 to 11]



wherein

X is an m-valent unit and

B are identical or different and denote K-R,

wherein

K is a bond or is $A^1-(A^2-A^3)_k$ -sp, wherein

X is an m-valent unit and

wherein

A^1 is $(CH_2)_tY(CH_2)_u$, wherein

Y is $>\text{C}=\text{O}$, $>\text{NH}$, $-\text{O}-$, $-\text{S}-$ or a bond,

t is an integer from 0 to 6 and

u is an integer from 0 to 6,

A² is -NHCO-, -CONH-, -OCONH- or SCONH-, or is -CO-,

A³ is (CH₂)_r, O(CH₂)_r, NH(CH₂)_r, S(CH₂)_r or -(CHQ)-, wherein

r is an integer from 1 to 6 and

Q is a substituted or unsubstituted alkyl or aryl group,

sp is a divalent spacer or a bond, and

k is an integer from 5 to 100, and

R is hydrogen; a ligand suitable for specific bonding to a receptor;

a marker molecule; or a catalytically active group; and

m is at least 2,

with the proviso that

- (1) in the compound at least one R is not hydrogen,
- (2) there are at least two K that are not a bond, and
- (3) X, B and m are so selected that an intermolecular association of the K in liquid phase by the formation of hydrogen bonds is possible, with formation of aggregates that present on the surface a plurality of R that are not hydrogen, and
- (4) the molar mass of the fragment $X(K)_m$ is less than 20,000.

Claim 13 has been canceled.

14. (Amended) [Process] A method according to claim [13] 27, further comprising [in the case of a solution of the compound addition of] adding a concentrated salt solution, [a change in] changing the pH or the temperature, or [addition of] adding organic solvents.

In re: Nikolai Vladimirovich Bovin et al.
 Serial No.: To Be Assigned
 Filed: Concurrently Herewith
 Page 22 of 30

15. (Amended) [Process] A method for changing the structure of [the] an aggregate [as defined in any one of claims 10 to 12, which comprises addition of] of the general formula (II)



wherein

X(B)_m may be identical or different and denote a compound of the general formula (I),



wherein

X is an m-valent unit and

B are identical or different and denote K-R,

wherein

K is a bond or is A¹-(A²-A³)_k-sp, wherein

A¹ is (CH₂)_tY(CH₂)_u, wherein

Y is >C=O, >NH, -O-, -S- or a bond,

t is an integer from 0 to 6 and

u is an integer from 0 to 6,

A² is -NHCO-, -CONH-, -OCONH- or SCONH-, or is -CO-,

A³ is (CH₂)_r, O(CH₂)_r, NH(CH₂)_r, S(CH₂)_r or -(CHQ)-, wherein

r is an integer from 1 to 6 and

Q is a substituted or unsubstituted alkyl or aryl group,

sp is a divalent spacer or a bond, and

k is an integer from 5 to 100, and

R is hydrogen; a ligand suitable for specific bonding to a receptor;

a marker molecule; or a catalytically active group; and

m is at least 2,

with the proviso that

(1) in the compound at least one R is not hydrogen,

(2) there are at least two K that are not a bond, and

(3) X, B and m are so selected that an intermolecular association of the K in liquid phase by the formation of hydrogen bonds is possible, with formation of aggregates that present on the surface a plurality of R that are not hydrogen, and

(4) the molar mass of the fragment X(K)_m is less than 20,000, and

In re: Nikolai Vladimirovich Bovin et al.
 Serial No.: To Be Assigned
 Filed: Concurrently Herewith
 Page 23 of 30

n is from 2 to 100,000,
and wherein $X(B)_m$ are non-covalently bonded,
further comprising adding a concentrated salt solution, [a change in] changing the
temperature or the pH [or an addition of] and/or adding urea, trifluoroethanol or peptides.

16. (Amended) [Process for] A method according to claim 27 further comprising
increasing the specific physiological activities of molecules by [their incorporation as]
incorporating a radical R into a compound of the general formula (I) [as defined in any one of
claims 1 to 9].

Claim 17 has been canceled.

18. (Amended) [Preparation according to claim 17 against] A method of treating
diseases arising from inflammation, viral and bacterial infections, influenza viruses, selectin-
mediated inflammatory processes, tumour metastases, or in the neutralisation of antibodies in
autoimmune disorders and transplants; said method comprising administering a compound of
the general formula (I)



wherein

X is an m-valent unit and

B are identical or different and denote K-R,

wherein

K is a bond or is $A^1-(A^2-A^3)_k\text{-sp}$, wherein

A^1 is $(CH_2)_tY(CH_2)_u$, wherein

Y is $>C=O$, $>NH$, $-O-$, $-S-$ or a bond,

t is an integer from 0 to 6 and

u is an integer from 0 to 6,

A^2 is $-NHCO-$, $-CONH-$, $-OCONH-$ or $SCONH-$, or is $-CO-$,

A^3 is $(CH_2)_r$, $O(CH_2)_r$, $NH(CH_2)_r$, $S(CH_2)_r$ or $-(CHQ)-$, wherein

r is an integer from 1 to 6 and

Q is a substituted or unsubstituted alkyl or aryl group,

sp is a divalent spacer or a bond, and

$$\{X(B)_m\}_n \quad (II)$$

X(B)_m may be identical or different and denote a compound of the general formula (I), and

n is from 2 to 100,000,

and wherein X(B)_m are non-covalently bonded.

20. (Amended) [Use of a compound as defined in any one of claims 1 to 9 or of an aggregate as defined in any one of claims 10 to 12 in the preparation of functionalised] A method according to claim 18 further comprising preparing functionalized molecular surfaces.

23. (Amended) [Compound] A compound of the general formula (III),

$$X(B)_m \quad (III)$$

In re: Nikolai Vladimirovich Bovin et al.
Serial No.: To Be Assigned
Filed: Concurrently Herewith
Page 25 of 30

wherein

X is an m-valent unit and

B are identical or different and denote K-H,

wherein

K is $A^1-(A^2-A^3)_k$ -sp, wherein

A¹ is (CH₂)_tY(CH₂)_u, wherein

Y is $>\text{C}=\text{O}$, $>\text{NH}$, $-\text{O}-$, $-\text{S}-$ or a bond,

t is an integer from 0 to 6 and

u is an integer from 0 to 6,

A² is -NHCO-, -CONH-, -OCONH- or SCONH-, or is -CO-,

A³ is (CH₂)_r, O(CH₂)_r, NH(CH₂)_r, S(CH₂)_r or -(CHQ)-, wherein

r is an integer from 1 to 6 and

Q is a substituted or unsubstituted alkyl or aryl group,

sp is a divalent spacer or a bond, and

k is an integer from 5 to 100, and

m is at least 2,

with the proviso that

- (1) X, B and m are so selected that an intermolecular association of the K in liquid phase is possible, especially under aqueous conditions, by the formation of hydrogen bonds, with formation of aggregates, and
- (2) the molar mass of the fragment $X(K)_m$ is less than 20,000, especially less than 4000.

Claim 24 has been canceled.

25. (New) A method of preparing a therapeutic drug comprising:
preparing a compound of the general formula (III),



wherein

X is an m -valent unit and

K is $A^1-(A^2-A^3)_k\text{-sp}$, wherein
 A^1 is $(\text{CH}_2)_t\text{Y}(\text{CH}_2)_u$, wherein
Y is $>\text{C}=\text{O}$, $>\text{NH}$, $-\text{O}-$, $-\text{S}-$ or a bond,
t is an integer from 0 to 6 and
u is an integer from 0 to 6,
 A^2 is $-\text{NHCO}-$, $-\text{CONH}-$, $-\text{OCONH}-$ or $\text{SCONH}-$, or is $-\text{CO}-$,
 A^3 is $(\text{CH}_2)_r$, $\text{O}(\text{CH}_2)_r$, $\text{NH}(\text{CH}_2)_r$, $\text{S}(\text{CH}_2)_r$ or $-(\text{CHQ})-$, wherein
r is an integer from 1 to 6 and
Q is a substituted or unsubstituted alkyl or aryl group,
sp is a divalent spacer or a bond, and
k is an integer from 5 to 100, and

with the proviso that

- (1) X, B and m are so selected that an intermolecular association of the K in liquid phase is possible, especially under aqueous conditions, by the formation of hydrogen bonds, with formation of aggregates, and
- (2) the molar mass of the fragment $X(K)_m$ is less than 20,000, especially less than 4000.

26. (New) A method of treating diseases arising from inflammation, viral and bacterial infections, influenza viruses, selectin-mediated inflammatory processes, tumour metastases, or in the neutralisation of antibodies in autoimmune disorders and transplants; said method comprising administering a compound of the general formula (III),



X is an m-valent unit and
B are identical or different and denote K-H,
wherein

K is $A^1-(A^2-A^3)_k\text{-sp}$, wherein
 A^1 is $(\text{CH}_2)_t\text{Y}(\text{CH}_2)_u$, wherein
Y is $>\text{C}=\text{O}$, $>\text{NH}$, $-\text{O}-$, $-\text{S}-$ or a bond,
t is an integer from 0 to 6 and
u is an integer from 0 to 6,
 A^2 is $-\text{NHCO}-$, $-\text{CONH}-$, $-\text{OCONH}-$ or $\text{SCONH}-$, or is $-\text{CO}-$,
 A^3 is $(\text{CH}_2)_r$, $\text{O}(\text{CH}_2)_r$, $\text{NH}(\text{CH}_2)_r$, $\text{S}(\text{CH}_2)_r$ or $-(\text{CHQ})-$, wherein
r is an integer from 1 to 6 and
Q is a substituted or unsubstituted alkyl or aryl group,
sp is a divalent spacer or a bond, and
k is an integer from 5 to 100, and
m is at least 2,

with the proviso that

- (1) X, B and m are so selected that an intermolecular association of the K in liquid phase is possible, especially under aqueous conditions, by the formation of hydrogen bonds, with formation of aggregates, and
- (2) the molar mass of the fragment $X(K)_m$ is less than 20,000, especially less than 4000.

27. (New) A method of preparing an aggregate comprising:
preparing a compound of the general formula (II)



wherein

X(B)_m may be identical or different and denote a compound of the general formula (I),



wherein

X is an m-valent unit and

B are identical or different and denote K-R,

wherein

K is a bond or is $A^1-(A^2-A^3)_k$ -sp, wherein


A¹ is (CH₂)_tY(CH₂)_u, wherein

Y is $>\text{C}=\text{O}$, $>\text{NH}$, $-\text{O}-$, $-\text{S}-$ or a bond,

In re: Nikolai Vladimirovich Bovin et al.
 Serial No.: To Be Assigned
 Filed: Concurrently Herewith
 Page 28 of 30

t is an integer from 0 to 6 and
 u is an integer from 0 to 6,
 A^2 is -NHCO-, -CONH-, -OCONH- or SCONH-, or is -CO-,
 A^3 is $(CH_2)_r$, $O(CH_2)_r$, $NH(CH_2)_r$, $S(CH_2)_r$ or $-(CHQ)-$, wherein
 r is an integer from 1 to 6 and
 Q is a substituted or unsubstituted alkyl or aryl group,
 sp is a divalent spacer or a bond, and
 k is an integer from 5 to 100, and
 R is hydrogen; a ligand suitable for specific bonding to a receptor;
 a marker molecule; or a catalytically active group; and
 m is at least 2,
 with the proviso that
 (1) in the compound at least one R is not hydrogen,
 (2) there are at least two K that are not a bond, and
 (3) X, B and m are so selected that an intermolecular association of the K in liquid phase
 by the formation of hydrogen bonds is possible, with formation of aggregates that
 present on the surface a plurality of R that are not hydrogen, and
 (4) the molar mass of the fragment $X(K)_m$ is less than 20,000, and
 n is from 2 to 100,000,
 and wherein $X(B)_m$ are non-covalently bonded.

28. (New) A method of preparing a therapeutic drug comprising:
 preparing the compound of the general formula (I)



wherein

X is an m-valent unit and

B are identical or different and denote K-R,

wherein

K is a bond or is $A^1-(A^2-A^3)_k-sp$, wherein

A^1 is $(CH_2)_tY(CH_2)_u$, wherein

Y is $>C=O$, $>NH$, -O-, -S- or a bond,

t is an integer from 0 to 6 and

In re: Nikolai Vladimirovich Bovin et al.

Serial No.: To Be Assigned

Filed: Concurrently Herewith

Page 29 of 30

u is an integer from 0 to 6,
 A^2 is -NHCO-, -CONH-, -OCONH- or SCONH-, or is -CO-,
 A^3 is $(CH_2)_r$, $O(CH_2)_r$, $NH(CH_2)_r$, $S(CH_2)_r$ or $-(CHQ)-$, wherein
 r is an integer from 1 to 6 and
 Q is a substituted or unsubstituted alkyl or aryl group,
 sp is a divalent spacer or a bond, and
 k is an integer from 5 to 100, and
 R is hydrogen; a ligand suitable for specific bonding to a receptor;
 a marker molecule; or a catalytically active group; and

m is at least 2,

with the proviso that

- (1) in the compound at least one R is not hydrogen,
- (2) there are at least two K that are not a bond, and
- (3) X, B and m are so selected that an intermolecular association of the K in liquid phase by the formation of hydrogen bonds is possible, with formation of aggregates that present on the surface a plurality of R that are not hydrogen, and
- (4) the molar mass of the fragment $X(K)_m$ is less than 20,000; or
 preparing the compound of the general formula (II):



wherein

$X(B)_m$ may be identical or different and denote a compound of the general formula (I), and

n is from 2 to 100,000,

and wherein $X(B)_m$ are non-covalently bonded; and

a pharmaceutically acceptable carrier.

29. (New) A method of preparing a diagnostic test comprising:

providing a test reagent

preparing a compound of the general formula (I)



wherein

B are identical or different and denote K-R, wherein

k is an integer from 5 to 100, and

with the proviso that

- (1) in the compound at least one R is not hydrogen,
- (2) there are at least two K that are not a bond, and
- (3) X, B and m are so selected that an intermolecular association of the K in liquid phase by the formation of hydrogen bonds is possible, with formation of aggregates that present on the surface a plurality of R that are not hydrogen, and
- (5) the molar mass of the fragment $X(K)_m$ is less than 20,000; or

preparing an aggregate of the general formula (II)



X(B)_m may be identical or different and denote a compound of the general formula (I), and

and comparing the test reagent to the compounds of the general formula (I) or (II).

(12) NACH DEM VERTRAG ÜBER DIE INTERNATIONALE ZUSAMMENARBEIT AUF DEM GEBIET DES
PATENTWESENS (PCT) VERÖFFENTLICHTE INTERNATIONALE ANMELDUNG(19) Weltorganisation für geistiges Eigentum
Internationales Büro(43) Internationales Veröffentlichungsdatum
11. Januar 2001 (11.01.2001)

PCT

(10) Internationale Veröffentlichungsnummer
WO 01/02018 A2(51) Internationale Patentklassifikation⁷: A61K 47/48

(21) Internationales Aktenzeichen: PCT/EP00/06139

(22) Internationales Anmeldedatum:
30. Juni 2000 (30.06.2000)

(25) Einreichungssprache: Deutsch

(26) Veröffentlichungssprache: Deutsch

(30) Angaben zur Priorität:
199 30 177.8 30. Juni 1999 (30.06.1999) DE(71) Anmelder (für alle Bestimmungsstaaten mit Ausnahme
von US): SYNTESOME GESELLSCHAFT FÜR
MEDIZINISCHE BIOCHEMIE MBH [DE/DE]; Heim-
dallstrasse 4, D-81739 München (DE).

(72) Erfinder; und

(75) Erfinder/Anmelder (nur für US): BOVIN, Nikolai
Vladimirovich [RU/RU]; ul. Artsimovicha, 11-181,
Moscow, 117871 (RU). TUSIKOV, Alexandr Borisovich
[RU/RU]; Ismailovsky prospect, 47-4, Moscoe, 105037(RU). CHINAREV, Alexandr Alexandrovich [RU/RU];
Berezhkovskaya naberezhnaya, 12-53, Moscow, 121059
(RU). DICUSAR, Mariya Alexandrovna [RU/RU];
3-i Nizhnelichoborsky proezd, 2/1-19, Moscow, 127238
(RU). GAMBARIYAN, Alexandra Sergeevna [RU/RU];
ul. Vardi, 40-71, Moscow, 117133 (RU). MARIN-
INA, Valentina Petrovna [RU/RU]; ul. Profsojuznaya,
140/2-273, Moscow, 117321 (RU).(74) Anwälte: HARTZ, Nikolai, F. usw.; Tal 29, D-80331
München (DE).(81) Bestimmungsstaaten (national): AE, AG, AL, AM, AT,
AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CU, CZ,
DE, DK, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,
ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,
LT, LU, LV, MD, MG, MK, MN, MW, MX, MZ, NO, NZ,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,
UA, UG, US, UZ, VN, YU, ZA, ZW.(84) Bestimmungsstaaten (regional): ARIPO-Patent (GH,
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), eura-
sisches Patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
europäisches Patent (AT, BE, CH, CY, DE, DK, ES, FI,
FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI-Patent

[Fortsetzung auf der nächsten Seite]

(54) Title: COMPOUNDS THAT ASSOCIATE ON THE INTERMOLECULAR LEVEL AND AGGREGATE BODIES THAT
CONTAIN THEM

(54) Bezeichnung: INTERMOLEKULAR ASSOZIIERENDE VERBINDUNGEN UND DIESE UMFASSENDE AGGREGATE

(57) Abstract: The invention relates to a compound of the general formula (I) $X(B)_m$, wherein X is a unit of the value m and the mem-
bers B are the same or different and represent K-R, wherein K represents a bond or $A^1-(A^2-A^3)_k$ -sp, wherein A^1 is $(CH_2)_tY(CH_2)_u$,
wherein Y is $>C=O$, $>NH$, $-O-$, $-S-$ or a bond, t is an integer from 0 to 6 and u is an integer from 0 to 6, A^2 represents $-NHCO-$,
 $-CONH-$, $-OCONH-$ or $SCONH-$, or $-CO-$, A^3 is $(CH_2)_r$, $O(CH_2)_r$, $NH(CH_2)_r$, $S(CH_2)_r$, or $-(CHQ)-$, wherein r is an integer from 1 to
6 and Q is a substituted or unsubstituted alkyl or aryl group, sp represents a bivalent spacer or a bond, and k is an integer from 5 to
100, and R represents hydrogen, a ligand that is suitable to specifically bind to a receptor, a marker molecule or a catalytically active
group, and m is at least 2, with the proviso that (1) in the compound at least one R is different from hydrogen, (2) at least 2 K are
present that do not represent a bond, and (3) X, the members B and m are selected in such a manner that K can be associated on the
intermolecular level in the liquid phase by the formation of hydrogen bonds and the simultaneous formation of aggregate bodies that
represent on their surfaces several R that are different from hydrogen, and (4) the molar mass of fragment $X(K)_m$ is less than 20.000.(57) Zusammenfassung: Verbindung der allgemeinen Formel (I): $X(B)_m$, wobei X für eine m-wertige Einheit steht und die B gleich
oder verschieden sind und für K-R stehen, wobei K für eine Bindung oder für $A^1-(A^2-A^3)_k$ -sp steht, wobei A^1 für $(CH_2)_tY(CH_2)_u$
steht, wobei Y für $>C=O$, $>NH$, $-O-$, $-S-$ oder eine Bindung, t für eine ganze Zahl von 0 bis 6 und u für eine ganze Zahl von 0 bis
6 steht, A^2 für $-NHCO-$, $-CONH-$, $-OCONH-$ oder $SCONH-$ steht, oder für $-CO-$ steht, A^3 für $(CH_2)_r$, $O(CH_2)_r$, $NH(CH_2)_r$, $S(CH_2)_r$,
oder $-(CHQ)-$ steht, wobei r für eine ganze Zahl von 1 bis 6 und Q für eine substituierte oder unsubstituierte Alkyl- oder Aryl-
Gruppe steht, sp für einen zweiwertigen Spacer oder eine Bindung steht, und k für eine ganze Zahl von 5 bis 100 steht, und R
für Wasserstoff, einen zur spezifischen Bindung an einen Rezeptor geeigneten Liganden, ein Marker-Molekül oder eine katalytisch
aktive Gruppe steht, und m mindestens 2 ist, mit der Massgabe, dass (1) in der Verbindung mindestens ein R nicht Wasserstoff ist, (2)
mindestens zwei K vorliegen, die nicht für eine Bindung stehen, und (3) X, die B und m so gewählt sind, dass eine intermolekulare
Assoziation der K in flüssiger Phase durch Bildung von Wasserstoffbrücken-Bindungen unter Ausbildung von Aggregaten, die auf
der Oberfläche mehrere R präsentieren, die nicht Wasserstoff sind, möglich ist, und (4) die Molmasse des Fragments $X(K)_m$ weniger
als 20.000 beträgt.

Intermolecularly associating compounds, and aggregates comprising them

The present invention relates to special low molecular weight compounds suitable for forming aggregates by intermolecular association. The present invention relates also to aggregates comprising such compounds, and to processes for the preparation of such aggregates. The invention relates also to special uses of the compounds and aggregates, especially for therapeutic and diagnostic purposes.

The simultaneous and specific association of at least two ligands with corresponding receptors results in multivalent interactions between two units carrying those ligands or receptors. Such multivalent interactions are very widespread in biology, it being possible for the interacting units to have ligands such as oligosaccharides, proteins, nucleic acids or lipids. Multivalent interactions are characterised by a large number of individual weak monovalent bonds which in biological systems are frequently preferred over a single strong monovalent bond (M. Mammen, S-K. Choi, G. M. Whitesides, *Angew. Chemie*, **110**, 2908, 1998).

In biological systems, multivalent interactions are frequently developed when bonds are formed between units with ligands and receptors having little affinity. Known examples of interactions between ligands and receptors having little affinity are carbohydrate-protein and carbohydrate-carbohydrate interactions (A. Danguy, K. Kayser, N. V. Bovin, H.-J. Gabius, *Trends Glycosc. Glycotech.*, **7**, 261, 1995), which, for example, in viral and bacterial infections play a crucial role in the onset of inflammatory processes, in the formation of tumour metastases or in immunorecognition.

Natural multivalent interactions can be blocked especially for therapeutic and diagnostic purposes. For the *in vitro* blocking of such multivalent interactions, both monovalent and multivalent inhibitors have been used hitherto.

In the case of derivatives of natural ligands as monovalent inhibitors it has been shown in practice that as a result of the low binding affinity it is not possible to achieve efficient inhibition of multivalent interactions. For example, the binding constant in the case of interaction between a monovalent galactoside and the corresponding lectin is only $K_D \sim 10^4 M$ (D. T. Connolly et al., *J. Biol. Chem.*, **257**, 939, 1982). For therapeutic use in such a case, very large amounts of inhibitor would have to be used. A method of treatment using such an inhibitor would not therefore be cost-effective.

Known multivalent inhibitors include those in which a plurality of ligands are covalently bonded to a low molecular weight carrier (L. L. Kiesling, N. L. Pohl, *Chemistry & Biology*, **3**, 71, 1996; G. D. Glick, P. L. Toogood, D. C. Wiley, J. J. Skehel, J. R. Knowles, *J. Biol. Chem.*, **266**, 23660, 1991) or to a dendrimer (D. Zanini, R. Roy, *J. Org. Chem.*, **63**, 3486, 1998). In those cases, however, the specific binding affinity is only very slightly increased.

WO 98/14215 discloses glucoconjugates as inhibitors of viral cell adhesion. In particular, the compound [Neu5Ac α 2-6Gal β 1-4GlcNAc β 1-NHCOCH₂NH-CO(CH₂)₄CO-(NHCH₂-CO)₃-NHCH₂]-₄C is disclosed. That compound does not, however, form aggregates in aqueous solution.

Also known are multivalent inhibitors in which the active ligands are bonded to a polymeric carrier. Such compounds exhibit increased efficiency in comparison with the corresponding monomeric ligands. By way of the example of the interaction between the influenza-haemagglutinin, which binds to neuraminic acid derivatives on the cell surface, it has been shown how the use of a polymer-based multivalent inhibitor affects that interaction (monovalent: $K_D \sim 2 \times 10^{-4}M$, multivalent: $K_D \sim 3 \times 10^{-7}M$; A. Spaltenstein et al., *J. Am. Chem. Soc.*, **113**, 686, 1991).

Despite their improved effectiveness, the multivalent polymeric inhibitors known hitherto are also unsuitable for therapeutic use. The disadvantages are to be attributed to the polymeric carrier molecules used and to the properties thereof.

When polylysine or sulfated polysaccharides are used as polymeric carriers, non-specific ionic interactions with cell surface structures take place.

Polyacrylamides and other polymers, the polymer content of which consists exclusively of C-C bonds, have the crucial disadvantage that they are broken down in the organism to form toxic metabolites.

High polymers (60-70 kDa) are not effectively filtered by the kidneys and their breakdown by the liver can lead to intolerances as a result of the formation of toxic metabolites.

Patent applications EP 601 417 and WO 95/34673 describe polymer-based carbohydrate receptor blockers that are physiologically tolerable both in the form of the total molecule

In the case of a medicament it is important to have accurate knowledge of the associations between the chemical structure of an active ingredient and its pharmacological properties. In the case of substance mixtures, it would have to be shown in what way the composition of a mixture influences its particular pharmacological properties. In addition, a medicament must be precisely defined in its chemical composition and must be demonstrably preparable in precisely that form. Neither requirement can be fulfilled in the case of the polymeric multivalent inhibitors using the synthetic and analytical methods currently available and using a technically sensible level of resources.

The problem underlying the present invention is therefore to avoid the disadvantages of the prior art and to make available new compounds having improved properties as multivalent inhibitors of biological recognition processes, the compounds having a specific action and being suitable for use as medicaments.

$$X(B)_m \quad (I)$$

X is an m-valent unit and
B are identical or different and denote K-R,
wherein

- 4 -

- K is a bond or is $A^1-(A^2-A^3)_k-sp$, wherein
- A^1 is $(CH_2)_tY(CH_2)_u$, wherein
- Y is $>C=O$, $>NH$, $-O-$, $-S-$ or a bond,
- t is an integer from 0 to 6 and
- u is an integer from 0 to 6,
- A^2 is $-NHCO-$, $-CONH-$, $-OCONH-$ or $SCONH-$,
- A^3 is $(CH_2)_r$, $O(CH_2)_r$, $NH(CH_2)_r$, $S(CH_2)_r$ or $-(CHQ)-$, wherein
- r is an integer from 1 to 6 and
- Q is a substituted or unsubstituted alkyl or aryl group,
- sp is a divalent spacer or a bond, and
- k is an integer from 5 to 100, and
- R is hydrogen; a ligand suitable for specific binding to a receptor; a marker molecule; or a catalytically active group; and
- m is at least 2,
- with the proviso that
- (1) in the compound at least one R is not hydrogen,
 - (2) there are at least two K that are not a bond, and
 - (3) X, B and m are so selected that an intermolecular association of the K in liquid phase by the formation of hydrogen bonds is possible, with formation of aggregates that present on the surface a plurality of R that are not hydrogen, and
 - (4) the molar mass of the fragment $X(K)_m$ is less than 20,000.

In the compound of formula (I), A^2 may also be $-CO-$.

Further preferred embodiments are the subject of the subsidiary claims.

In a preferred embodiment, the molar mass of the fragment $X(K)_m$ is less than 10,000, preferably less than 4,000.

Self-association of compounds of the general formula (I) gives rise to aggregates that act as highly efficient multivalent inhibitors of biological recognition processes.

In the compounds of formula (I), X, B and m are so selected that an intermolecular association of the K in liquid phase is possible, especially under aqueous conditions,

preferably under *in vivo* conditions, with formation of aggregates that present on the surface a plurality of R that are not hydrogen.

It has been found that by the formation of the aggregates according to the invention the disadvantages of the previously known multivalent active ingredients can be avoided.

It has been found especially that the slight increase in binding affinity in comparison with a monovalent active ingredient where a plurality of ligands are covalently bonded to a low molecular weight carrier or to a dendrimer is to be attributed to the fact that although such molecules do present a plurality of ligands, the latter cannot be arranged (or only some of them can be arranged) in such a manner that a thermodynamically advantageous interaction with receptors is achieved. It has been found that the interaction of a polyvalent active ingredient can be improved by dynamically coupling the ligand arrangement to the receptor arrangement. It has been found that this dynamic coupling can be achieved by way of an intermolecular aggregate formation in which special molecular regions of the active ingredient associate intermolecularly and thus an adaptation of the ligand arrangement is facilitated. Finally, it has been found that the adaptation of the ligand arrangement so facilitated results in a drastic increase in the binding affinity of the polyvalent active ingredient.

By virtue of the reversibility of the aggregate formation, the compounds of the present invention enable a molecular unit to interact polyvalently with a plurality of receptors, with subsequent optimisation of the ligand arrangement, there being found a thermodynamically advantageous arrangement without any undesirable side effects, such as the insertion of the compounds into the cell membrane.

The compounds of the present invention are small molecules, which would not be expected to have an action as antigen, and the other disadvantages that occur with polymeric polyvalent active ingredients are also avoided.


The molecular structure of the compounds of general formula (I) is substantially distinguished by three structural features:

- an m-valent fragment X,
- a plurality of molecule chains K, which are covalently bonded to the fragment X,
- at least one terminal group R, which is a ligand suitable for specific binding to a receptor; a marker-molecule; or a catalytically active group.

The molecule chains K are distinguished by a chemical structure that allows an inter-molecular association in liquid phase also under aqueous conditions, especially *in vivo* conditions, with formation of aggregates. The formation of the aggregates is based on non-covalent interactions, it being possible for the non-covalent interactions to be ionic interactions, van der Waals interactions, hydrophobic interactions or preferably hydrogen bonds. The structure of non-covalent bonds between a plurality of compounds of the general formula (I) brings about a self-association and thus the formation of aggregates.

The compounds of the general formula (I) have at least one terminal group R that is derived, for example, from a biologically active ligand or from a marker. The terminal groups R are covalently bonded to the terminal ends of the molecule chains serving for the association. The bonding of those groups can be effected directly or by way of a spacer. As spacer there can be used a divalent molecular fragment which does not participate in the intermolecular association brought about by non-covalent interactions, but which merely serves to hold the terminal groups R. Such a spacer is formally part of the molecule chain K.

According to the invention, K in the formula (I) may be



wherein

- A^1 is $(CH_2)_t Y (CH_2)_u$, wherein
 Y is $>C=O$, $>NH$, $-O-$, $-S-$ or a bond,
 t is an integer from 0 to 6 and
 u is an integer from 0 to 6,
 A^2 is $-NHCO-$, $-CONH-$, $-OCONH-$ or $SCONH-$,
 A^3 is $(CH_2)_r$, $O(CH_2)_r$, $NH(CH_2)_r$, $S(CH_2)_r$ or $-(CHQ)-$, wherein
 r is an integer from 1 to 6 and
 Q is a substituted or unsubstituted alkyl or aryl group,
 sp is a divalent spacer or a bond, and
 k is an integer from 5 to 100.

In the compound of formula (I), A^2 may also be $-CO-$.

Special preference is given to compounds of the general formula (I), wherein

- m is an integer from 2 to 4, and
- X is CH_{4-m} , NH_{3-m} , N^+H_{4-m} , $>\text{P}-$ (when $m = 3$), $>\text{P}^+<$ (when $m = 4$), $>\text{B}-$ (when $m = 3$), a linear atom group C_2H_{6-m} , $>\text{CH}(\text{CH}_2)_z\text{CH}<$, $>\text{C}=\text{C}<$, $>\text{N}-\text{N}<$, $>\text{N}(\text{CH}_2)_z\text{N}<$ wherein $z = 2 - 6$, when $m = 4$), a carbocyclic atom group C_6H_{6-m} , $\text{C}_6\text{H}_{12-m}$, or a heterocyclic atom group C_3N_3 (when $m = 3$), C_4N_2 (when $m = 4$).

It is especially preferable for at least 3 K to be present in a compound of the general formula (I). Special preference is given to compounds of the general formula (I) in which at least two R, preferably three R, are not hydrogen.

When more than one terminal group R is present in a compound of the general formula (I), those groups may be identical or different.

As examples of the ligands suitable for specific binding to a receptor that function as terminal groups R of compounds of the general formula (I) there may be mentioned naturally occurring biological recognition structures, such as mono- or oligo-saccharides, peptides, mono- or oligo-nucleotides or nucleic bases. It is also possible, however, to use synthetic derivatives of those compounds or other organic or inorganic compounds that are recognised by biological receptors. As ligands there may also be used known compounds that are used in free form as therapeutic active ingredients. There may be mentioned by way of example:

- anti-tumour agents, such as, for example, daunomycin, doxorubicin, vinblastine, bleomycin;
- antibiotics, such as, for example, penicillins, erythromycins, azidamfenicol, cefalotin and griseofulvin;
- antagonists of blood platelet activation factors;
- leucotriene antagonists;
- inhibitors of the cyclooxygenase system, such as, for example, salicylic acid compounds;
- lipxygenase inhibitors;
- antiphlogistics, such as, for example, indometacin;
- antirheumatics, such as, for example, nifenazone;
- therapeutic radionuclides, such as, for example, bismuth;
- neuraminidase;

- inhibitors, such as, for example, zanamivir.

It is preferable to use oligosaccharides that are present on cell surfaces as constituents of glycoproteins, glycolipids or proteoglycans, and also any desired constituent parts thereof.

Special oligosaccharides that can be used as terminal group R are as follows: sialic acid, sialyl lactose, sialyl lactosamine, lactose, $\text{Gal}\alpha 1-3\text{Gal}$, $\text{Gal}\alpha 1-3(\text{Fuc}\alpha 1-2)\text{Gal}$, $\text{GalNAc}\alpha 1-3(\text{Fuc}\alpha 1-2)\text{Gal}$, $\text{Neu5Ac}\alpha 2-6\text{GalNAc}$, SiaLe^A , SiaLe^X , HSO_3Le^A , HSO_3Le^X , $\text{Gal}\alpha 1-3\text{Gal}\beta 1-4\text{GlcNAc}$, $\text{Gal}\alpha 1-3\text{Gal}\beta 1-4\text{Glc}$, $\text{Neu5Ac}\alpha 2-6\text{Gal}\beta 1-4\text{GlcNAc}$.

In addition, preference is given to sialic acid benzyl glycoside, $\text{HSO}_3\text{GlcA}\beta 1-3\text{Gal}$, $\text{HSO}_3\text{GlcA}\beta 1-3\text{Gal}\beta 1-4\text{GlcNAc}\beta 1-3\text{Gal}\beta 1-4\text{Glc}$, $\text{GalNAc}\alpha$, $\text{GalNAc}\alpha 1-3(\text{Fuc}\alpha 1-2)\text{Gal}\beta 1-4\text{GlcNAc}$, $\text{Gal}\alpha 1-3(\text{Fuc}\alpha 1-2)\text{Gal}\beta 1-4\text{GlcNAc}$, $\text{HSO}_3(\text{Sia})\text{Le}^X$, $\text{HSO}_3(\text{Sia})\text{Le}^A$, Le^Y , $\text{GlcNAc}\beta 1-6(\text{GlcNAc}\beta 1-3)\text{Gal}\beta 1-4\text{Glc}$, $\text{GalNAc}\beta 1-4(\text{Neu5Ac}\alpha 2-3)\text{Gal}\beta 1-4\text{Glc}$, mannose-6-phosphate, $\text{GalNAc}\beta 1-4\text{GlcNAc}$, oligo-sialic acid, N-glycolylneuraminic acid, $\text{Gal}\alpha 1-4\text{Gal}\beta 1-4\text{Glc}$, $\text{Gal}\alpha 1-4\text{Gal}\beta 1-4\text{GlcNAc}$.

Derivatives or mimetics of the above-mentioned mono- or oligo-saccharides, peptides, mono- or oligo-nucleotides or nucleic bases can also be used.

The terminal groups R can also be derived from marker molecules. Such marker molecules enable compounds of the general formula (I) to be used in diagnostic applications. All marker molecules known to the person skilled in the art for *in vitro* diagnostic test systems, such as, for example, biotin, fluorescein, rhodamine, digoxigenin or radioactive markers, come into consideration for the purposes of the present invention. Special mention may be made of markers known to the person skilled in the art for *in vivo* diagnosis, such as radioactive markers that contain a bound radionuclide, e.g. technetium, X-ray contrast media that contain e.g. an iodised compound, or nuclear resonance contrast media, e.g. based on gadolinium compounds.

It is proposed that in a preferred embodiment the terminal groups R be so selected that aggregates are obtained which, on the one hand, interact with suitable receptors by way of suitable ligands through polyvalent interactions and, on the other hand, contain marker units. As a result, the polyvalent interactions are accessible to detection and the compounds can be used in a diagnostic procedure.

The aggregates can in this case be synthesised from compounds of formula (I) that contain both ligands and the marker radicals. Such an aggregate preferably comprises only one special compound of the general formula (I). On the other hand, however, an aggregate can also comprise a plurality of different compounds of formula (I), the compounds containing either ligands or marker radicals.

The present invention also provides an aggregate of the following general formula (II)



wherein

X(B)_m may be identical or different and denote a compound of the general formula (I), as defined in any one of claims 1 to 11, and

n is from 2 to 100,000,

and wherein $X(B)_m$ are non-covalently bonded.

The present invention provides especially an aggregate having a leaf-like structure and having linear, cyclic, polycyclic, polyhedral, spherical or dendritic structure. The aggregates may consist of two or more different compounds of the general formula (I).

The present invention also provides compounds of the general formula (III). The compounds of general formula (III) correspond to those of formula (II) wherein all terminal groups R are hydrogen atoms. Such compounds can be used with the compounds of the general formula (I) described above in order to alter the properties of the aggregates.

The present invention provides especially a compound of the general formula (III)



wherein

X is an m-valent unit and

B are identical or different and denote K-H,

wherein

K is $A^1-(A^2-A^3)_k$ -sp,

wherein

A^1 is $(CH_2)_tY(CH_2)_u$, wherein
 Y is $>C=O$, $>NH$, $-O-$, $-S-$ or a bond,
 t is an integer from 0 to 6 and
 u is an integer from 0 to 6,
 A^2 is $-NHCO-$, $-CONH-$, $-OCONH-$ or $SCONH-$,
 A^3 is $(CH_2)_r$, $O(CH_2)_r$, $NH(CH_2)_r$, $S(CH_2)_r$ or $-(CHQ)-$, wherein
 r is an integer from 1 to 6 and
 Q is a substituted or unsubstituted alkyl or aryl group,
 sp is a divalent spacer or a bond, and
 k is an integer from 5 to 100, and


m is at least 2,

with the proviso that

- (1) X , B and m are so selected that an intermolecular association of the K in liquid phase is possible, especially under aqueous conditions, by the formation of hydrogen bonds, with formation of aggregates, and
- (2) the molar mass of the fragment $X(K)_m$ is less than 20,000, especially less than 4000.

In the compound of formula (III), A^2 may also be $-CO-$.

In a preferred embodiment, K in formula (III) is



wherein


A^1 is $(CH_2)_tY(CH_2)_u$, wherein
 Y is $>C=O$, $>NH$, $-O-$, $-S-$ or a bond,
 t is an integer from 0 to 6 and
 u is an integer from 0 to 6,
 A^2 is $-NHCO-$, $-CONH-$, $-OCONH-$ or $SCONH-$,
 A^3 is $(CH_2)_r$, $O(CH_2)_r$, $NH(CH_2)_r$, $S(CH_2)_r$ or $-(CHQ)-$, wherein
 r is an integer from 1 to 6 and
 Q is a substituted or unsubstituted alkyl or aryl group,
 sp is a divalent spacer or a bond, and
 k is an integer from 5 to 100.

Fig. 2 shows the relative particle size distribution of aggregate $\{[\text{Neu5Ac-Gab-Ad-AC}_3\text{-Gly}_5\text{-NHCH}_2\text{-}]_4\text{C}\}_x$, 20°C H₂O;

Fig. 3 shows the influence of temperature and of the presence of urea on the particle size of aggregate $\{[\text{Neu5Ac-Gab-Ad-Gly}_7\text{-NHCH}_2\text{-}]_4\text{C}\}_x$

The aggregates are high molecular weight non-covalent polymers that are formed by self-association of compounds of the general formula (I) (Scheme 3).

Scheme 3



That intermolecular association takes place spontaneously and results in the formation of stable and ordered structures. The course of that process depends upon the molecular structure of the compounds of the general formula (I) used and upon the external conditions. The molar masses, sizes and shapes of the aggregates formed are likewise determined by those factors.

The non-covalent nature of the bonds between the compounds of the general formula (I) gives rise to the reversibility of the aggregate formation and, in the event of a change in the external conditions, allows dissociation of the aggregates to form compounds of the general formula (I) or conversion thereof into other aggregates, in each case with a view to forming the most thermodynamically stable structures.

The self-association of compounds of the general formula (I) to form aggregates can be observed both in solution and on surfaces.

By means of scanning tunnel microscopy (STM) and atomic force microscopy it has been shown that the aggregate $\{[\text{Neu5Ac-Gab-Ad-Gly}_7\text{-NHCH}_2\text{-}]_4\text{C}\}_x$ forms ordered chain structures on a graphite substrate.

The formation of aggregates in solution can be observed by light scattering experiments or by gel permeation chromatography.

The compound of the general formula (I) $\text{Neu5Ac-Gab-AC}_m\text{-Ad-Gly}_5\text{-NHCH}_2\text{-}]_4\text{C}$ ($m=1-3$) associates at room temperature in aqueous and organic solvents. Investigation into the associates formed in water using gel permeation chromatography showed the formation of aggregates having molecular weights of about 2000 kD, as shown in Figure 1.

Investigation into the association of the compound of the general formula (I) [Neu5Ac-Gab-Ad-AC₃-Gly₅-NHCH₂]₄C in water at 20°C showed the formation of three types of aggregates having particle sizes between 25 and 2000 nm (Figure 2). When the sample was heated to 60°C, a reduction in the relative proportion of the smaller particles was observed, while at the same time the relative proportion of the larger particles increased and the total number of particles decreased. An increase in aggregate size with temperature was also observed in the case of the compound of the general formula (I) (48). That compound forms in water at 60°C particles having sizes of up to 8000 nm (Figure 3).

External conditions that determine the formation of the aggregates and the course of the intermolecular association include, in addition to temperature, the pH value and the nature and composition of the solvent. By means of light scattering experiments it has been shown that the compound $[\text{HCl}\cdot\text{H-Gly}_7\text{-NHCH}_2\text{-}]_4\text{C}$ (**22a**) in water at 20°C is present in non-associated form, but by the addition of a 0.8M NaHCO_3 solution a self-association of the compound is achieved. The addition of HCl then enables the association to be reversed again (cf. Example 9).

The formation of aggregates is also influenced by the presence of components that are able to enter into interactions with the compounds of the general formula (I). Those components may be organic molecules, such as, for example, compounds of the formula (III), urea (Figure 3), trifluoroethanol, methanol, acetone or other organic solvents. There may also be other compounds of the general formula (I) or (III) that on their own - under the given conditions - do not form associates.

In the case of compounds of the general formula (I) and aggregates, the process of self-association is influenced also by the interactions between the ligands and the corresponding receptors. That influence may, for example, be such that only as a result of the presence of the receptors is an association of compounds of the general formula (I) brought about, more specifically under conditions in which association of those compounds would not otherwise take place. As a result of the reversibility of the aggregate formation it is equally possible that aggregates, in the presence of receptors, change in such a manner, with rearrangement or modification of the composition, that a thermodynamically advantageous state of the entire system consisting of aggregate and receptor is achieved. The aggregates can therefore adapt themselves to different receptor arrangements and thus optimise an interaction between the receptors and

ligands. That optimisation by subsequent adaptation of the polyvalent interactions constitutes a substantial advantage over the prior art.

Special biologically active aggregates will now be described. As a result of the self-association of compounds of the general formula (I) with biologically active ligands there are formed biologically active aggregates that act as highly effective multivalent inhibitors of biological recognition processes. The specific activity of such an inhibitor is dependent upon the affinity of terminal groups R, and also upon the "matrix" of the aggregate, that is to say the structure of the compound of the general formula (I) used as carrier.

Tables 2 and 3 show the influence of the matrix structure on the inhibition of the viral cell adhesion of influenza viruses, measured in a fetuin binding assay known to the person skilled in the art. That assay reveals an increase in the specific activity of the inhibitor by more than three orders of magnitude in comparison with the activity of the free ligand Neu5Ac α Bn in the case of the aggregate {[Neu5Ac-Gab-Ad-AC₃-Gly₅-NHCH₂]₄C}_x (**44**).

Table 1

Inhibition of viral cell adhesion of influenza viruses, strain A/NIB/44/90M H3N2, FBI test, Neu5Ac α Bn as a reference compound, specific activity per Neu5Ac group

Inhibitor	Relative activity
Neu5Ac α -OBn	1
[Neu5Ac-Gab-Ad-Gly _n -NHCH ₂] ₄ C (n=0-5)	2
[Neu5Ac-Ap-Ad-Gly _n -NHCH ₂] ₄ C (n=3-5)	1
[Neu5Ac-Gab-Ad-GlyGluGly-NHCH ₂] ₄ C	5
[Neu5Ac-Gab-AC-Ad-Gly ₅ -NHCH ₂] ₄ C	15
[Neu5Ac-Gab-AC ₂ -Ad-Gly ₅ -NHCH ₂] ₄ C	330
[Neu5Ac-Gab-AC ₃ -Ad-Gly ₅ -NHCH ₂] ₄ C	1000
[Neu5Ac-Gab-Ad-AC ₂ -Gly ₅ -NHCH ₂] ₄ C	1000
[Neu5Ac-Gab-Ad-AC ₃ -Gly ₅ -NHCH ₂] ₄ C	2500

Table 2

Inhibition of viral cell adhesion of influenza viruses inhibition of strain A/Duck/Alberta/60/67 H12N5, FBI test, 3`SL as a reference compound, specific activity per 3`SL group

Inhibitor	Relative activity
3'SL	1
[3'SL-NHCOCH ₂ NH-Ad-Gly ₅ -NHCH ₂] ₄ C	20
[3'SL-NHCOCH ₂ NH-Ad-Gly ₇ -NHCH ₂] ₄ C	200

A further example of the increase in biological activity of a biological ligand resulting from its binding to an aggregate is the compound $\{[B_{\alpha}Ap-Ad-AC_3-Gly_5-NHCH_2]_4C\}_x$ (**49**) as inhibitor of the cytotoxicity of human blood sera with respect to porcine kidney cells PK15. The aggregate (**49**) exhibits a specific activity three orders of magnitude higher than the free ligand Gal α 1-3Gal (B disaccharide).

Abbreviations used:

Np	para-nitrophenyl
NOS	N-oxy succinimidyl
Boc	tert-butyloxycarbonyl
AC	6-aminocaproyl
Ad	1,6-hexanedioyl
Ap	3-aminopropyl
Gab	4-(glycylamido)-benzyl
Sug	carbohydrate radical
SL	sialyl lactose
Bn	benzyl
LC	column chromatography
TLC	thin-layer chromatography

The invention will now be described in greater detail with reference to Examples.

Materials and methods:

¹H-NMR spectra (δ, ppm, TMS) were recorded using a spectrometer of the WM-500 type from Bruker (USA) at 303°K.

Mass spectra were recorded using a time-of-flight spectrometer of the MSBCh type (Sumy, Ukraine) (ionisation by cleavage products of californium-252 at an acceleration voltage of +15 eV).

The light scattering experiments were carried out using the following apparatus: Coultronics Coulter N4-MD (He-Ne laser, $\lambda=632.8$ nm, measurement of the scattering at an angle of 62.5° to the incident light beam), Spectra-Physics 164 (argon laser, $\lambda=528.7$ nm and $\lambda=611.5$ nm, measurement of the scattering at an angle of 90° to the incident light beam).

Silica gel 60 (40-63 μm) (Merck) was used for column chromatography. Sephadex of types LH-20, G-10, G-25 (Pharmacia, Sweden) and TSK-4000 (HPLC) were used for gel permeation chromatography.

For TLC, silica gel 60 (Merck) and silica gel 60 glass plates with fluorescent indicator F254 (Merck) were used. For the detection of spots on the TLC plates, the following methods were used:

- heating after spraying with a 7% H_3PO_4 solution (carbohydrate compounds);
- heating after spraying with a 2% ninhydrin solution in ethanol (compounds having primary amino groups);
- heating after a dwell time of 10 minutes in a chamber over conc. HCl and subsequent spraying with a 2% ninhydrin solution in ethanol (compounds having Boc-protected amino groups);
- dwell time of 10 minutes in a chamber over conc. NH_3 (4-nitrophenyl ester);
- observing the plates under UV.

For TLC, the following eluant systems were used:

- A – toluene/ethyl acetate 2:1
- B – acetone/ethyl acetate/methanol 10:4:1
- C – CHCl_3 /MeOH 7:1
- D – CHCl_3 /ethyl acetate/MeOH/AcOH 9:3:2:0.2
- E – iPrOH/ethyl acetate/ H_2O 2:3:1
- F – EtOH/ NH_3 (aq) 2:1
- G – iPrOH/ethyl acetate/ H_2O 4:3:2
- H – iPrOH/acetone/ H_2O 4:3:2

Preparation of known starting compounds

Tetrakis(aminomethyl)methane tetrahydrochloride (1)

was prepared analogously to the literature (E. B. Fleischer, A.E. Gebala, A. Levey, P.A. Tasker, *J.Org.Chem.*, **36**, 3042, 1971).

TLC: $R_f=0.6$; eluant – 25% ammonia/water; developer – ninhydrin.

M.p $>300^{\circ}\text{C}$.

¹H-NMR spectrum in D₂O (δ, ppm): 3.45 (s, CH₂).

4-Nitrophenyl trifluoroacetate (2)

was prepared analogously to the literature (S. Sakakibara, N. Inukai, *Bull.Chem.Soc.Jap.*, **37**, 1231, 1964).

Di-(4-nitrophenyl) adipate (3)

was prepared analogously to the literature (S. Sakakibara, N. Inukai, *Bull.Chem.Soc.Jap.*, **37**, 1231, 1964).

$R_f=0.76$, eluant D A.

¹H-NMR spectrum in CDCl₃ (δ, ppm): 1.871 (m, 4H, 2 COCH₂CH₂), 2.666 (m, 4H, 2 COCH₂), 7.255 and 8.240 (m, 8H, J_{2,3} 9Hz, Ar).

Methyl [4-(tert-butyloxycarbonyl-glycylamido)benzyl 5-acetamido-4,7,8,8-tetra-O-acetyl-3,5-dideoxy- α -D-glycero-D-galacto-nonulopyranosid]oate

Ac₄(OMe)Neu5Ac-Gab-Boc (4)

was prepared analogously to the literature (US Patent 5,571,836, 1996).

¹H-NMR spectrum (CDCl₃, δ, ppm): 1.448 (s, 9H, CMe₃), 1.849, 1.994, 2.008, 2.111, 2.127 (s, 5x3H, 5 Ac), 1.979 (dd, 1H, H-3_{ax} Neu5Ac), 2.613 (dd, 1H, J₄ 4.6 Hz, J_{3ax} 12.9 Hz, H-3_{eq} Neu5Ac), 3.637 (s, 3H, COOCH₃), 3.882 (d, 2H, J 6 Hz, COCH₂NH), 4.058 (ddd, 1H, H-5 Neu5Ac), 4.074 (dd, 1H, J_{9b} 12.5 Hz, J₈ 5.9 Hz, H-9a Neu5Ac), 4.112 (dd, 1H, J₅ 10.6, J₇ 2.3 Hz, H-6 Neu5Ac), 4.299 (dd, 1H, J_{9b} 12.5 Hz, J₈ 2.7 Hz, H-9b Neu5Ac), 4.366 and 4.735 (d, 2x1H, J 12 Hz, OCH₂Ar), 4.847 (ddd, 1H, J₅ 10 Hz, J_{3ax} 12.3 Hz, J_{3eq} 4.6 Hz, H-4 Neu5Ac), 5.24 (br., 1H, NH_{Boc}), 5.251 (d, 1H, J₅ 9.8 Hz, NH), 5.314 (dd, 1H, J₆ 2.3 Hz, J₈ 8.2 Hz, H-7 Neu5Ac), 5.424 (ddd, 1H, H-8 Neu5Ac), 7.258 and 7.445 (d, 2x2H, J 8.4 Hz, Ar), 8.144 (br. s, 1H, NHAr).

Neu5Ac α 2-3Gal β 1-4Glc β -NHCOCH $_2$ NH $_2$ (12)

was prepared analogously to the literature (L.M. Likhoshesterov, O.S. Novikova, V.A. Derevitskaja, N.K. Kochetkov, *Carbohydrate Research*, **146**, C1-C5, 1986; and I.D. Manger, T.W. Rademacher, R.A. Dwek, *Biochemistry*, **31**, 10724, 1992).

$^1\text{H-NMR}$ spectrum (D_2O , δ , ppm): 1.82 (dd, 1H, H-3 $_{\text{ax}}$ Neu5Ac, J_4 12 Hz), 2.06 (s, 3H, NAc), 2.79 (dd, 1H, H-3 $_{\text{eq}}$ Neu5Ac, $J_{3\text{ax}}$ 12.4 Hz, J_4 4.6 Hz), 3.48 (m, 1H, H-2 Glc, J_3 9 Hz), 3.61 (dd, 1H, H-2 Gal), 3.99 (dd, 1H, H-4 Gal), 4.14 (dd, 1H, H-3 Gal, J_2 9.8 Hz, J_4 3.1 Hz), 4.57 (d, 1H, H-1 Gal, J_2 7.8 Hz), 5.09 (d, 1H, H-1 Glc, J_2 9.3 Hz).

Gal α 1-3Gal β -O(CH $_2$) $_3$ NH $_2$ (13)

was prepared analogously to the literature (E. Yu. Korchagina, N. V. Bovin, *Bioorganicheskaya Khimiya*, 1992, **18**, 283, Rus).

The compounds *BocGlyNOS*, *BocGlyGlyNOS* and *BocAC-ONp* were prepared using N,N'-dicyclohexylcarbodiimide analogously to the literature (G. W. Anderson, J. E. Zimmerman, F. M. Callahan, *J. Amer. Chem. Soc.*, **86**, 1839, 1964; M. Bodanszky, V. du Vigneaud, *J. Amer. Chem. Soc.*, **81**, 5688, 1959).

Example 1.

Preparation of Ac $_4$ (OMe)Neu5Ac-Gab-AC-Boc (5).

10 ml of CHCl_3 and 2 ml of CF_3COOH were added to 0.5 mmol of compound (4). The reaction mixture was stirred at room temperature for one hour; 2 ml of toluene were added and the mixture was concentrated by evaporation *in vacuo* and dried. The residue was dissolved in 10 ml of CHCl_3 , and 1.5 mmol of 6-N-Boc-amino-(4-nitrophenyl) hexanoate and 0.3 ml of NEt_3 were added. The reaction mixture was stirred at room temperature for 24 hours and concentrated by evaporation *in vacuo*. The resulting residue was chromatographed over silica gel.

The compounds **Ac $_4$ (OMe)Neu5Ac-Gab-AC $_2$ -Boc (6)** and **Ac $_4$ (OMe)Neu5Ac-Gab-AC $_3$ -Boc (7)** were prepared in an analogous manner (see Table 4).

Table 3 (Example 1)

Product	Starting compound	TLC: eluant A, R _f	Column chromatography	Yield, %
Ac₄(OMe)Neu5Ac-Gab-AC-Boc (5)	(4)	0.6	CHCl ₃ /MeOH 35:1 → 10:1	90
Ac₄(OMe)Neu5Ac-Gab-AC₂-Boc (6)	(5)	0.45	acetone/ethyl acetate/MeOH 10:4:0.5 → 10:4:3	72
Ac₄(OMe)Neu5Ac-Gab-AC₃-Boc (7)	(6)	0.25	acetone/ethyl acetate/MeOH 10:4:1 → 10:4:5	70

¹H-NMR spectra (CDCl₃, δ, ppm):

Ac₄(OMe)Neu5Ac-Gab-AC-Boc (5): 1.331, 1.468, 1.655 (m, 3CH₂), 1.402 (s, 9H, CMe₃), 2.264 (t, 2H, J 7.5 Hz, CH₂CONHCH₂CO), 3.066 (m ~ quadr, 2H, J 6.6 Hz, CH₂NHBoc), 4.060 (d, 2H, J 5 Hz, COCH₂NH), 4.364 and 4.733 (d, 2x1H, J 12 Hz, OCH₂Ar), 4.571 (br., 1H, NHBoc), 6.521 (br., 1H, COCH₂NHCO), 7.253 and 7.460 (d, 2x2H, J 8.4 Hz, Ar), 8.547 (br. s, 1H, NHAr).

Neu5Acα fragment: (see (4)).

Ac₄(OMe)Neu5Ac-Gab-AC₂-Boc (6): 1.280, 1.338, 1.447, 1.482, 1.582, 1.655, 2.107 (m, 7CH₂), 1.403 (s, 9H, CMe₃), 2.276 (t, 2H, J 7.2 Hz, CH₂CONHCH₂CO), 3.060 (m ~ quadr, 2H, J 6.6 Hz, CH₂NHBoc), 3.216 (m ~ quadr, 2H, J 6.4 Hz, CH₂NH), 4.040 (d, 2H, J 5 Hz, COCH₂NH), 4.353 and 4.728 (d, 2x1H, J 12 Hz, OCH₂Ar), 4.651 (br., 1H, NHBoc), 5.793 (t, 1H, J 5 Hz, CH₂NHCO), 6.714 (br., 1H, COCH₂NHCO), 7.245 and 7.467 (d, 2x2H, J 8.4 Hz, Ar), 8.666 (br. s, 1H, NHAr). Neu5Acα fragment: (see (4)).

Ac₄(OMe)Neu5Ac-Gab-AC₃-Boc (7): 1.283, 1.336, 1.447, 1.482, 1.594, 1.655, 2.117 (m, 11CH₂), 1.401 (s, 9H, CMe₃), 2.282 (t, 2H, J 7.2 Hz, CH₂CONHCH₂CO), 3.045 (m ~ quadr, 2H, J 6.6 Hz, CH₂NHBoc), 3.214 (m ~ quadr, 4H, J 6.4 Hz, CH₂NH), 4.040 (d, 2H, J 5 Hz, COCH₂NH), 4.353 and 4.728 (d, 2x1H, J 12 Hz, OCH₂Ar), 4.669 (br., 1H, NHBoc), 5.876 (t, 1H, J 5.5 Hz, CH₂NHCO), 6.071 (br., 1H, CH₂NHCO), 6.940 (br., 1H, COCH₂NHCO), 7.242 and 7.483 (d, 2x2H, J 8.4 Hz, Ar), 9.033 (br. s, 1H, NHAr).

Neu5Acα fragment: (see (4)).

Example 2.

Preparation of Ac₄(OMe)Neu5Ac-Gab-AC-Ad-ONp (9).

10 ml of CHCl₃ and 2 ml of CF₃COOH were added to 0.5 mmol of compound (5). The reaction mixture was stirred at room temperature for one hour; 5 ml of toluene were added and the mixture was concentrated by evaporation *in vacuo* and dried. The residue

was dissolved in 15 ml of tetrahydrofuran; 5 mmol of compound **(3)** and 0.3 ml of NEt_3 were added and the reaction mixture was stirred at room temperature for 24 hours. The excess NEt_3 was neutralised with CH_3COOH and the reaction mixture was concentrated by evaporation. The residue was dissolved in CHCl_3 and the resulting solution was washed with water and concentrated by evaporation. The resulting mixture was chromatographed over a column of silica gel (see Table 4).

The compounds **$\text{Ac}_4(\text{OMe})\text{Neu5Ac-Gab-Ad-ONp}$ (8)**, **$\text{Ac}_4(\text{OMe})\text{Neu5Ac-Gab-AC}_2\text{-Ad-ONp}$ (10)** and **$\text{Ac}_4(\text{OMe})\text{Neu5Ac-Gab-AC}_3\text{-Ad-ONp}$ (11)** were prepared in an analogous manner (see Table 4).

Table 4 (Example 2)

Product	Starting compound	TLC: eluant C, R_f	Column chromatography	Yield, %
$\text{Ac}_4(\text{OMe})\text{Neu5Ac-Gab-Ad-ONp}$ (8)	(4)	0.6	$\text{CHCl}_3/i\text{-PrOH}$ 20:1	78
$\text{Ac}_4(\text{OMe})\text{Neu5Ac-Gab-AC-Ad-ONp}$ (9)	(5)	0.55	$\text{CHCl}_3/\text{MeOH}/\text{AcOH}$ 35:1:0.2 \rightarrow 15:1:0.2	65
$\text{Ac}_4(\text{OMe})\text{Neu5Ac-Gab-AC}_2\text{-Ad-ONp}$ (10)	(6)	0.48	$\text{CHCl}_3/\text{MeOH}/\text{AcOH}$ 35:1:0.2 \rightarrow 15:1:0.2	60
$\text{Ac}_4(\text{OMe})\text{Neu5Ac-Gab-AC}_3\text{-Ad-ONp}$ (11)	(7)	0.43	$\text{CHCl}_3/\text{MeOH}/\text{AcOH}$ 35:1:0.2 \rightarrow 15:1:0.2	62

$^1\text{H-NMR}$ -spectra:

$\text{Ac}_4(\text{OMe})\text{Neu5Ac-Gab-Ad-ONp}$ (8) (CDCl_3 , δ , ppm): 1.774 (m, 2H, $\text{CH}_2\text{CH}_2\text{COO}$), 1.843, 1.984, 2.00, 2.100, 2.117 (s, 5x3H, 5 Ac), 1.966 (dd, 1H, H-3_{ax} Neu5Ac), 2.335 and 2.393 (m, 2x1H, $\text{CH}_2\text{CH}_2\text{CONH}$), 2.601 (t, 2H, J 6Hz, $\text{CH}_2\text{CH}_2\text{COO}$), 2.604 (dd, 1H, H-3_{eq} Neu5Ac), 3.645 (s, 3H, COOCH_3), 3.688 (t, 2H, J 4.7Hz, $\text{CH}_2\text{CH}_2\text{CONH}$), 4.049 (ddd, 1H, H-5 Neu5Ac), 4.062 (dd, 1H, J₈ 6_Hz, H-9a Neu5Ac), 4.074 (d, 2H, J_{NH} 5.5Hz, COCH_2NHCO), 4.111 (dd, 1H, J₅ 10.7, J₇ 2.3Hz, H-6 Neu5Ac), 4.298 (dd, 1H, J_{9b} 12.5Hz, J₈ 2.9Hz, H-9b Neu5Ac), 4.343 and 4.722 (d, 2x1H, J 12Hz, OCH_2Ar), 4.839 (ddd, 1H, J₅ 10.2Hz, J_{3ax} 12.3Hz, J_{3eq} 4.6Hz, H-4 Neu5Ac), 5.307 (dd, 1H, J₈ 8.4Hz, J₆ 2.3Hz, H-7 Neu5Ac), 5.359 (d, 1H, J₅ 9.7Hz, NH), 5.406 (ddd, 1H, H-8 Neu5Ac), 6.616 (t, 1H, COCH_2NHCO), 7.243 and 7.450 (d, 2x2H, J 8.5Hz, $p\text{-C}_6\text{H}_4\text{NH}$), 7.221 and 8.208 (d, 2x2H, J 9Hz, $p\text{-C}_6\text{H}_4\text{NO}_2$), 8.586 (s, 1H, NHAr).

$\text{Ac}_4(\text{OMe})\text{Neu5Ac-Gab-AC-Ad-ONp}$ (9) (CDCl_3 , δ , ppm): 1.341 (m, 2H, $\text{COCH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{NH}$), 1.495 and 1.666 (m, 2x2H, $\text{COCH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{NH}$), 1.729 (m, 2H, $\text{CH}_2\text{CH}_2\text{COO}$), 1.856, 1.991, 2.010, 2.110 and 2.129 (s, 5x3H, 5 Ac), 1.976 (dd, 1H, H-3_{ax} Neu5Ac), 2.138, 2.175 (m, 2x1H, $\text{CH}_2\text{CH}_2\text{CONH}$), 2.182 and 2.267 (t,

2x2H, 2 CH₂CONH), 2.601 (~t, 2H, J 6.8Hz, CH₂CH₂COO), 2.611 (dd, 1H, J_{3ax} 12.8, J₄ 4.5Hz, H-3_{eq} Neu5Ac), 3.228 (m ~ quadr, 2H, J 6.6Hz, CH₂NHCO), 3.645 (s, 3H, COOCH₃), 4.022 (d, 2H, J_{NH} 5.4Hz, COCH₂NHCO), 4.050 (ddd, 1H, H-5 Neu5Ac), 4.065 (dd, 1H, J₈ 6Hz, H-9a Neu5Ac), 4.113 (dd, 1H, J₅ 10.8, J₇ 2.3Hz, H-6 Neu5Ac), 4.295 (dd, 1H, J_{9a} 12.5Hz, J₈ 2.9Hz, H-9b Neu5Ac), 4.357 and 4.732 (d, 2x1H, J 12Hz, OCH₂Ar), 4.848 (ddd, 1H, J₅ 10Hz, J_{3ax} 12.2Hz, J_{3eq} 4.5Hz, H-4 Neu5Ac), 5.170 (d, 1H, J₅ 10Hz, NH), 5.308 (dd, 1H, J₈ 8.6Hz, J₆ 2.3Hz, H-7 Neu5Ac), 5.413 (ddd, 1H, H-8 Neu5Ac), 5.708 (t, 1H, CH₂CH₂NHCO), 6.483 (t, 1H, COCH₂NHCO), 7.251 and 7.427 (d, 2x2H, J 8.7Hz, *p*-C₆H₄NH), 7.243 and 8.224 (d, 2x2H, J 9Hz, *p*-C₆H₄NO₂), 8.298 (s, 1H, NHAr). **Ac₄(OMe)Neu5Ac-Gab-AC₂-Ad-ONp (10)** (D₆-DMSO, δ, ppm): 1.231, 1.376, 1.485 and 1.608 (m, CH₂), 1.757 (dd, 1H, H-3_{ax} Neu5Ac), 1.678, 1.917, 1.974, 2.023 and 2.092 (s, 5x3H, 5 Ac), 2.570 (dd, 1H, J_{3ax} 12.4, J₄ 4.5Hz, H-3_{eq} Neu5Ac), 2.638 (t, 2H, J 7Hz, CH₂CH₂COO), 3.009 (m, 4H, 2CH₂NHCO), 3.699 (s, 3H, COOCH₃), 3.859 (d, 2H, J_{NH} 5.9Hz, COCH₂NHCO), 3.904 (ddd, 1H, H-5 Neu5Ac), 4.027 (dd, 1H, J₈ 6.2Hz, H-9a Neu5Ac), 4.089 (dd, 1H, J₅ 10.8, J₇ 2.6Hz, H-6 Neu5Ac), 4.235 (dd, 1H, J_{9a} 12.4Hz, J₈ 3.1Hz, H-9b Neu5Ac), 4.322 and 4.645 (d, 2x1H, J 11.7Hz, OCH₂Ar), 4.715 (ddd, 1H, J₅ 10Hz, J_{3ax} 12Hz, J_{3eq} 4.5Hz, H-4 Neu5Ac), 5.193 (dd, 1H, J₈ 8.4Hz, J₆ 2.Hz, H-7 Neu5Ac), 5.341 (ddd, 1H, H-8 Neu5Ac), 7.216 and 7.554 (d, 2x2H, J 8.4Hz, *p*-C₆H₄NH), 7.433 and 8.296 (d, 2x2H, J 9.2Hz, *p*-C₆H₄NO₂), 7.674 (t, 1H, J 5.5Hz, CH₂CH₂NHCO), 7.706 (d, 1H, J₅ 9.8Hz, NH), 7.754 (t, 1H, J 5.8Hz, CH₂CH₂NHCO), 8.081 (t, 1H, J 5.9Hz, COCH₂NHCO), 9.961 (s, 1H, NHAr).

Ac₄(OMe)Neu5Ac-Gab-AC₃-Ad-ONp (11) (D₆-DMSO, δ, ppm): 1.214, 1.360, 1.478, 1.609 (m, CH₂), 2.639 (t, 2H, J 7Hz, CH₂CH₂COO), 2.999 (m, 6H, 3CH₂NHCO), 3.864 (d, 2H, J_{NH} 5.9Hz, COCH₂NHCO), 4.324 and 4.645 (d, 2x1H, J 11.7Hz, OCH₂Ar), 7.212 and 7.568 (d, 2x2H, J 8.4Hz, *p*-C₆H₄NH), 7.435 and 8.295 (d, 2x2H, J 9.2Hz, *p*-C₆H₄NO₂), 7.700 (m, 2H, 2CH₂CH₂NHCO), 7.750 (t, 1H, J 5.8Hz, CH₂CH₂NHCO), 8.122 (t, 1H, J 5.9Hz, COCH₂NHCO), 10.047 (s, 1H, NHAr), Neu5Acα fragment: see (10).

Example 3.

Preparation of

Neu5Acα2-3Galβ1-4Glcβ-NHCOCH₂NHCO(CH₂)₄COO(4-C₆H₄NO₂) (14).

119 mg (0.172 mmol) of compound (12) in 0.5 ml of DMSO were added, while stirring, to a solution of 334 mg (0.86 mmol) of compound (3) in 2 ml of DMF. The mixture was stirred at 20°C for 24 hours. After the addition of 200 µl of AcOH, the reaction mixture was diluted with 15 ml of water. The solution was filtered and the filtrate was concentrated

to a volume of ~ 2 ml. The residue was poured onto a Sephadex LH-20 column (1.5x50 cm) and eluted with MeCN/H₂O (1:1, 0.2% AcOH). After isolation, 140 mg of (**14**) were obtained, corresponding to a yield of 87 %. TLC: R_f 0.41 (eluant H).

¹H-NMR spectrum (D₂O, δ, ppm): 1.737 (m, 1H, CH₂CH₂CH₂CO), 1.779 (dd, 1H, H-3_{ax} Neu5Ac, J₄ 12.5 Hz), 2.003 (s, 3H, NAc), 2.383 (t, 1H, J 7 Hz, CH₂CO), 2.733 (dd, 1H, H-3_{eq} Neu5Ac, J_{3ax} 12.5 Hz, J₄ 4.5 Hz), 3.432 (m, 1H, H-2 Glc, J₃ 9 Hz), 3.556 (dd, 1H, H-2 Gal), 3.933 (dd, 1H, H-4 Gal), 4.090 (dd, 1H, H-3 Gal, J₂ 10 Hz, J₄ 3 Hz), 4.499 (d, 1H, H-1 Gal, J₂ 8 Hz), 4.985 (d, 1H, H-1 Glc, J₂ 9 Hz).

The compound **Neu5Ac-Gab-Ad-ONp (15)** was prepared analogously starting from (**3**) and Neu5Acα-OCH₂(*p*-C₆H₄)-NHCOCH₂NH₂ (US Patent 5,571,836, 1996).

¹H-NMR spectrum (CD₃OD, δ, ppm): 1.968 (dd, 1H, H-3_{ax} Neu5Ac), 1.980 (m, 4H, CH₂CH₂CH₂CO), 2.205 (s, 3H, NCOCH₃), 2.565 and 2.874 (t, 2x2H, J 6.8 Hz, 2 CH₂CO), 2.976 (dd, 1H, J₄ 4.5 Hz, J_{3ax} 13 Hz, H-3_{eq} Neu5Ac), 3.743 (dd, 1H, J₆ 1.5 Hz, J₈ 9 Hz, H-7 Neu5Ac), 3.821 (dd, 1H, J₅ 10 Hz, H-6 Neu5Ac), 3.840 (dd, 1H, J_{9b} 12 Hz, J₈ 6 Hz, H-9a Neu5Ac), 3.924 (ddd, 1H, H-4 Neu5Ac), 3.978 (ddd, 1H, H-5 Neu5Ac), 4.047 (dd, 1H, J₈ 2 Hz, H-9b Neu5Ac), 4.083 (ddd, 1H, H-8 Neu5Ac), 4.196 (s, 2H, COCH₂NH), 4.653 and 4.973 (d, 2x1H, J 11 Hz, OCH₂Ar), 7.474 and 7.707 (d, 2x2H, J 8.3 Hz, *p*-C₆H₄NH), 7.561 and 8.467 (d, 2x2H, J 8.8 Hz, *p*-C₆H₄NO₂).

The compound **Galα1-3Galβ-O(CH₂)₃NHCO(CH₂)₄COO(*p*-C₆H₄NO₂) (16)** was prepared analogously starting from (**3**) and Galα1-3Galβ-O(CH₂)₃NH₂ (**13**).

¹H-NMR spectrum (D₂O, δ, ppm): 1.78 (m, 4H, CH₂CH₂), 1.89 (m, 2H, CH₂), 2.36 (t, 2H, CH₂COO), 2.77 (m, 2H, NHCOCH₂), 3.36 (m, 2H, CH₂N), 3.69 (t, 1H, J₃ 9 Hz, 2-Galβ), 3.76 (m, 1H, OCH'), 3.78 (m, 6,6'-Galα), 3.91 (dd, 1H, J₃ 10 Hz, 2-Galα), 4.00 (dd, 1H, 3-Galα), 4.01 (m, 1H, OCH), 4.06 (br. d, 1H, 4-Galα), 4.20 (br. d, 1H, 4-Galβ), 4.23 (br. t, 1H, 5-Galα), 4.48 (d, 1H, J₂ 8 Hz, 1-Galβ), 5.19 (d, 1H, J₂ 4 Hz, 1-Galα), 8.38, 7.43 (d, 2x2H, J 9.5 Hz, Ar).

Example 4.

Tetra-(*N*-tert-butyloxycarbonyl-pentaglycilamidomethyl)methane [BocGly₅-NHCH₂]₄C (**21**).

1 mmol of compound (**19**) (see Table 5) was taken up in 4 ml of CF₃COOH and stirred at room temperature for two hours. 4 ml of toluene were added and the reaction mixture

was concentrated by evaporation *in vacuo* and dried. The residue was dissolved in 5 ml of water; 4 ml of a 2M HCl solution were added and concentration was carried out. The resulting tetrahydrochloride (**19a**) was dried *in vacuo* and suspended in 0.5 ml of DMF; 6 mmol of BocGlyGlyNOS and 0.5 ml of NEt₃ were added and the mixture was stirred at room temperature for 24 hours. The reaction mixture was concentrated *in vacuo* and the product was purified by column chromatography. After drying *in vacuo*, compound (**21**) was obtained in the form of a white powder in a yield of 69% (see Table 5).

Compounds (**17**)-(20), (**22**)-(25) were prepared in an analogous manner (see Table 5).

¹H-NMR spectra (for the allocation of the ¹H-NMR signals, the glycines within the chains were numbered, the numbering beginning in each case at the N-terminal end of the chains).

[BocGly-NHCH₂-]₄C (17). ¹H-NMR spectrum in D₆-DMSO (δ, ppm): 1.366 (s, 9H, OMe₃), 2.759 (br. d, 2H, CCH₂), 3.494 (d, 2H, J_{NH} 6 Hz, CH₂^{Gly}), 7.368 (t, 1H, NH^{Gly}), 7.969 (br. t, 1H, CCH₂NH), mass spectrum: 783 (M+Na).

[HCl·H-Gly₂-NHCH₂-]₄C (18a). ¹H-NMR spectrum in D₂O (δ, ppm): 2.952 (s, 2H, CCH₂), 3.966 (s, 2H, CH₂^{Gly}), 4.013 (s, 2H, CH₂^{Gly}).

[BocGly₃-NHCH₂-]₄C (19). ¹H-NMR spectrum in D₆-DMSO (δ, ppm): 1.375 (s, 9H, OMe₃), 2.690 (br. d, 2H, J_{NH} 6.5 Hz, CCH₂), 3.586 (d, 2H, J_{NH} 6 Hz, CH₂^{Gly3}), 3.725 (d, 2H, J_{NH} 5.5 Hz, CH₂^{Gly1}), 3.847 (d, 2H, J_{NH} 5.5 Hz, CH₂^{Gly2}), 6.976 (t, 1H, NH^{Gly3}), 7.811 (t, 1H, NH^{Gly2}), 7.975 (t, 1H, CCH₂NH), 8.534 (t, 1H, NH^{Gly1}), mass spectrum: 1239 (M+Na).

[BocGly₄-NHCH₂-]₄C (20). ¹H-NMR spectrum in D₆-DMSO (δ, ppm): 1.374 (s, 9H, OMe₃), 2.694 (br. d, 2H, CCH₂), 3.575 (d, 2H, CH₂^{Gly4}), 3.707 (d, 2H, CH₂^{Gly1}), 3.750 (d, 2H, CH₂^{Gly3}), 3.835 (d, 2H, CH₂^{Gly2}), 6.980 (t, 1H, NH^{Gly4}), 7.827 (t, 1H, CCH₂NH), 8.048 (t, 1H, NH^{Gly3}), 8.096 (t, 1H, NH^{Gly2}), 8.590 (t, 1H, NH^{Gly1}), mass spectrum: 1467 (M+Na).

[BocGly₅-NHCH₂-]₄C (21). ¹H-NMR spectrum in D₆-DMSO (δ, ppm): 1.380 (s, 9H, OMe₃), 2.688 (br. d, 2H, CCH₂), 3.579 (d, 2H, J_{NH} 6 Hz, CH₂^{Gly5}), 3.718 (d, 2H, J_{NH} 5 Hz, CH₂^{Gly1}), 3.750 (d, 4H, J_{NH} ~5 Hz, CH₂^{Gly3,4}), 3.840 (d, 2H, J_{NH} 5.5 Hz, CH₂^{Gly2}), 6.974 (t, 1H, NH^{Gly5}), 7.770 (t, 1H, CCH₂NH), 8.006 (t, 1H, NH^{Gly4}), 8.075 and 8.102 (t, 1H, NH^{Gly2,3}), 8.550 (t, 1H, NH^{Gly1}), mass spectrum: 1695 (M+Na), 1711 (M+K).

[BocGly₇-NHCH₂-]₄C (22). ¹H-NMR spectrum in D₆-DMSO (δ, ppm): 1.378 (s, 9H, OMe₃), 2.688 (br., 2H, CCH₂), 3.581 (d, 2H, CH₂^{Gly7}), 3.723 (br. d, 2H, CH₂^{Gly1}), 3.751 (m, 8H, CH₂^{Gly3-6}), 3.840 (br. d, 2H, CH₂^{Gly2}), 6.970 (br. t, 1H, NH^{Gly7}), 7.814 (br. t, 1H,

CCH₂NH), 8.018 (br. t, 1H, NH^{Gly6}), 8.081, 8.085, 8.092 and 8.118 (m, 4H, NH^{Gly2-5}), 8.545 (br. t, 1H, NH^{Gly1}).

[HCl·H-AC-Gly₅-NHCH₂]₄C (23a). ¹H-NMR spectrum in D₂O (δ, ppm): 1.446 (m, 2H, CH₂), 1.689 (m, 2H, COCH₂CH₂), 1.724 (m, 2H, CH₂CH₂N), 2.398 (t, 2H, J 7.4 Hz, COCH₂), 2.967 (br. s, CCH₂), 3.044 (t, 2H, J 7.4 Hz, CH₂N), 3.994, 4.012, 4.049 (x2) and 4.096 (s, 10H, 5 COCH₂N).

[HCl·H-AC₂-Gly₅-NHCH₂]₄C (24a). ¹H-NMR spectrum in D₂O (δ, ppm): 1.336 and 1.382 (m, 4H, 2 CH₂), 1.548 (m, 2H, CH₂CH₂N), 1.656 (m, 4H, 2 COCH₂CH₂), 1.712 (m, 2H, CH₂CH₂N⁺), 2.283 (t, 2H, J 7.4 Hz, COCH₂), 2.370 (t, 2H, J 7.4 Hz, COCH₂NHCOCH₂), 2.955 (br. s, CCH₂), 3.031 (t, 2H, J 7.4 Hz, CH₂N⁺), 3.206 (t, 2H, J 6.6 Hz, CH₂N), 3.988, 4.00, 4.044 (x2) and 4.091 (s, 10H, 5 COCH₂N).

[HCl·H-AC₃-Gly₅-NHCH₂]₄C (25a). ¹H-NMR spectrum in D₂O (δ, ppm): 1.34-1.42 (m, 6H, 3 CH₂), 1.551 (m, 4H, 2 CH₂CH₂N), 1.653 (x2) and 1.689 (m, 6H, 3 COCH₂CH₂), 1.717 (m, 2H, CH₂CH₂N⁺), 2.270 and 2.288 (t, 4H, J 7.5 Hz, 2 COCH₂), 2.376 (t, 2H, J 7.5 Hz, COCH₂NHCOCH₂), 2.952 (br. s, CCH₂), 3.033 (t, 2H, J 7.5 Hz, CH₂N⁺), 3.208 (t, 4H, J 7 Hz, 2 CH₂N), 3.990, 4.004, 4.049 (x2) and 4.097 (s, 10H, 5 COCH₂N).

Table 5. Preparation of tetravalent matrices (17)-(25) (Example 4)

Table 5. Preparation of tetraivalent matrices (17)-(25) (Example 4)									
End product	Starting compound	Carboxylate	Conditions	TLC			Isolation of the products	Yield %	
				Boc derivative		Tetrahydrochloride			
				Rf	Eluant	Rf			Eluant
[BocGly ₁ -NHCH ₂ -I ₄ C (17)]	(1)	6 mM BocGlyNOS	24 hours stirring in DMF at room temperature	0.5	D	0.72	F	The reaction mixture was concentrated by evaporation <i>in vacuo</i> and (17) obtained by crystallisation from trifluoromethanol after addition of CHCl ₃ /ethyl acetate/MeOH (9/3/1)	78
[BocGly ₂ -NHCH ₂ -I ₄ C (18)]	(1)	6 mM BocGlyGlyNOS		-	-	0.72		The product (18) is only very slightly soluble, it was isolated by filtration and, after removal of the Boc protecting groups, identified as tetrahydrochloride (18a)	95
[BocGly ₃ -NHCH ₂ -I ₄ C (19)]	(17)			0.79	acetone/MeOH/H ₂ O 15 1 1	0.61		The reaction mixture was concentrated by evaporation <i>in vacuo</i> Column chromatography: acetone/MeOH/H ₂ O 30 1.1→15 1 1	77
[BocGly ₄ -NHCH ₂ -I ₄ C (20)]	(18)			0.48	E	0.55		The reaction mixture was concentrated by evaporation <i>in vacuo</i> Column chromatography: acetone/MeOH/H ₂ O 30 1.1→10.1 1	63
[BocGly ₅ -NHCH ₂ -I ₄ C (21)]	(19)			0.36		0.33		69	
[BocGly ₇ -NHCH ₂ -I ₄ C (22)]	(21)	12 mM BocNH(CH ₂) ₅ -COONp	DMSO, 70°C 72 hours	-	-	0.67	2N HCl	The product (22) is only very slightly soluble, it was isolated by filtration and, after removal of the Boc protecting groups, identified as tetrahydrochloride (22a)	93
[Boc-AC-Gly ₅ -NHCH ₂ -I ₄ C (23)]	(21)			0.38	G	0.22		71	The products, after chromatography over Sephadex LH-20, MeCN/H ₂ O 1 1 and after removal of the Boc protecting groups, identified as tetrahydrochlorides (23a), (24a) and (25a)
[Boc-AC ₂ -Gly ₅ -NHCH ₂ -I ₄ C (24)]	(23)			0.73		0.1		57	
[Boc-AC ₃ -Gly ₅ -NHCH ₂ -I ₄ C (25)]	(24)			0.4		-		40	

Example 5.

Preparation of protected tetrasialosides

Preparation of [Ac₄(OMe)Neu5Ac- α -OCH₂(p-C₆H₄)NHCOCH₂NH-CO(CH₂)₄CO-(NHCH₂CO)₅NHCH₂]₄C

[Ac₄(OMe)Neu5Ac-Gab-Ad-Gly₅-NHCH₂]₄C (31).

1 mmol of compound (21) (see Table 6) was taken up in 4 ml of CF₃COOH and the mixture was stirred at room temperature for two hours. 4 ml of toluene were added and the reaction mixture was concentrated by evaporation *in vacuo* and dried. The residue was dissolved in 5 ml of water; 4 ml of a 2M HCl solution were added and the mixture was concentrated. The resulting tetrahydrochloride (21a) was dried *in vacuo* and suspended in 0.5 ml of DMF; 6 mmol of Ac₄(OMe)Neu5Ac-Gab-Ad-ONp (8) and 0.5 ml of NEt₃ were added and the mixture was stirred at room temperature for 24 hours. The reaction mixture was concentrated *in vacuo* and the product was purified by means of column chromatography (see Table 6). After drying *in vacuo*, the compound (21) was obtained in the form of a colourless amorphous product in a yield of 65%.

Compounds (26)-(30), (32)-(36) were prepared in an analogous manner (see Table 6).

[Ac₄(OMe)Neu5Ac-Gab-Ad-NHCH₂]₄C (26). ¹H-NMR spectrum in D₆-DMSO (δ , ppm): matrix: 1.534 (m, 4H, 2 COCH₂CH₂), 2.171 (m, 4H, 2 COCH₂CH₂), 2.891 (br., 2H, CCH₂), 3.867 (d, 2H, ArNHCOCH₂), 7.674 (br. t, 1H, CCH₂NH), 8.107 (t, 1H, J 6 Hz, NHCOCH₂CH₂), 9.964 (s, 1H, ArNH); Neu5Ac α 2-OCH₂C₆H₄ fragment: 1.677, 1.918, 1.975, 2.024 and 2.094 (s, 15H, 5 COCH₃), 1.761 (dd, 1H, J₄ 12.2 Hz, H-3ax), 2.570 (dd, 1H, J_{3ax} 12.5 Hz, J₄ 4.6 Hz, H-3eq), 3.697 (s, 3H, COOCH₃), 3.904 (ddd, 1H, J₄ 10.3 Hz, H-5), 4.028 (dd, 1H, J₈ 6.3 Hz, H-9b), 4.087 (dd, 1H, J₅ 10.7 Hz, H-6), 4.233 (dd, 1H, J_{9b} 12.5 Hz, J₈ 3 Hz, H-9a), 4.320 and 4.643 (d, 2H, J 11.8 Hz, ArCH₂), 4.711 (ddd, 1H, H-4), 5.192 (dd, 1H, J₈ 8.4 Hz, J₆ 2.4 Hz, H-7), 5.341 (ddd, 1H, H-8), 7.214 and 7.555 (d, 2H, J 8.6 Hz, Ar), 7.708 (d, 1H, J₅ 9.6 Hz, NH).

[Ac₄(OMe)Neu5Ac-Gab-Ad-Gly-NHCH₂]₄C (27). ¹H-NMR spectrum in D₆-DMSO (δ , ppm): matrix: 1.509 (m, 4H, 2 COCH₂CH₂), 2.147 and 2.231 (m, 4H, 2 COCH₂CH₂), 2.674 (br., 2H, CCH₂), 3.647 (m, 2H, Gly), 3.859 (d, 2H, ArNHCOCH₂), 7.852 (br. t, 1H, CCH₂NH), 8.100 (t, 1H, J 6 Hz, NHCOCH₂CH₂), 8.453 (t, 1H, J 6 Hz, NHGly), 9.962 (s, 1H, ArNH). Neu5Ac α 2-OCH₂C₆H₄ fragment: 1.677, 1.918, 1.975, 2.024 and 2.094 (s, 15H, 5 COCH₃), 1.761 (dd, 1H, J₄ 12.2 Hz, H-3ax), 2.570 (dd, 1H, J_{3ax} 12.5 Hz, J₄ 4.6 Hz, H-3eq), 3.697 (s, 3H,

COOCH₃), 3.904 (ddd, 1H, J₄ 10.3 Hz, H-5), 4.028 (dd, 1H, J₈ 6.3 Hz, H-9b), 4.087 (dd, 1H, J₅ 10.7 Hz, H-6), 4.233 (dd, 1H, J_{9b} 12.5 Hz, J₈ 3 Hz, H-9a), 4.320 and 4.643 (d, 2H, J 11.8 Hz, ArCH₂), 4.711 (ddd, 1H, H-4), 5.192 (dd, 1H, J₈ 8.4 Hz, J₆ 2.4 Hz, H-7), 5.341 (ddd, 1H, H-8), 7.214 and 7.555 (d, 2H, J 8.6 Hz, Ar), 7.708 (d, 1H, J₅ 9.6 Hz, NH).

[Ac₄(OMe)Neu5Ac-Gab-Ad-Gly₂-NHCH₂]₄C (28). ¹H-NMR spectrum in D₆-DMSO (δ, ppm): matrix: 1.495 (m, 4H, 2 COCH₂CH₂), 2.150 (m, 4H, 2 COCH₂CH₂), 2.694 (br., 2H, CCH₂), 3.716 (d, 2H, CH₂^{Gly2}), 3.818 (d, 2H, CH₂^{Gly1}), 3.865 (d, 2H, ArNHCOCH₂), 7.824 (br. t, 1H, CCH₂NH), 7.993 (t, 1H, J 6 Hz, NH^{Gly2}), 8.096 (t, 1H, J 6 Hz, NHCOCH₂CH₂), 8.544 (t, 1H, J 6 Hz, NH^{Gly1}), 9.975 (s, 1H, ArNH). Neu5Acα2-OCH₂C₆H₄ fragment: 1.677, 1.918, 1.975, 2.024 and 2.094 (s, 15H, 5 COCH₃), 1.761 (dd, 1H, J₄ 12.2 Hz, H-3ax), 2.570 (dd, 1H, J_{3ax} 12.5 Hz, J₄ 4.6 Hz, H-3eq), 3.697 (s, 3H, COOCH₃), 3.904 (ddd, 1H, J₄ 10.3 Hz, H-5), 4.028 (dd, 1H, J₈ 6.3 Hz, H-9b), 4.087 (dd, 1H, J₅ 10.7 Hz, H-6), 4.233 (dd, 1H, J_{9b} 12.5 Hz, J₈ 3 Hz, H-9a), 4.320 and 4.643 (d, 2H, J 11.8 Hz, ArCH₂), 4.711 (ddd, 1H, H-4), 5.192 (dd, 1H, J₈ 8.4 Hz, J₆ 2.4 Hz, H-7), 5.341 (ddd, 1H, H-8), 7.214 and 7.555 (d, 2H, J 8.6 Hz, Ar), 7.708 (d, 1H, J₅ 9.6 Hz, NH).

[Ac₄(OMe)Neu5Ac-Gab-Ad-Gly₃-NHCH₂]₄C (29). ¹H-NMR spectrum in D₆-DMSO (δ, ppm): matrix: 1.498 (m, 4H, 2 COCH₂CH₂), 2.143 and 2.158 (m, 4H, 2 COCH₂CH₂), 2.693 (br., 2H, CCH₂), 3.728 (m, 4H, 2 CH₂^{Gly2,3}), 3.841 (d, 2H, CH₂^{Gly1}), 3.862 (d, 2H, ArNHCOCH₂), 7.820 (br. t, 1H, CCH₂NH), 8.049 and 8.059 (t, 2H, J 5.7 Hz, NH^{Gly2,3}), 8.098 (t, 1H, J 5.8 Hz, NHCOCH₂CH₂), 8.547 (t, 1H, J 5.5 Hz, NH^{Gly1}), 9.972 (s, 1H, ArNH). Neu5Acα2-OCH₂C₆H₄ fragment: 1.677, 1.918, 1.975, 2.024 and 2.094 (s, 15H, 5 COCH₃), 1.761 (dd, 1H, J₄ 12.2 Hz, H-3ax), 2.570 (dd, 1H, J_{3ax} 12.5 Hz, J₄ 4.6 Hz, H-3eq), 3.697 (s, 3H, COOCH₃), 3.904 (ddd, 1H, J₄ 10.3 Hz, H-5), 4.028 (dd, 1H, J₈ 6.3 Hz, H-9b), 4.087 (dd, 1H, J₅ 10.7 Hz, H-6), 4.233 (dd, 1H, J_{9b} 12.5 Hz, J₈ 3 Hz, H-9a), 4.320 and 4.643 (d, 2H, J 11.8 Hz, ArCH₂), 4.711 (ddd, 1H, H-4), 5.192 (dd, 1H, J₈ 8.4 Hz, J₆ 2.4 Hz, H-7), 5.341 (ddd, 1H, H-8), 7.214 and 7.555 (d, 2H, J 8.6 Hz, Ar), 7.708 (d, 1H, J₅ 9.6 Hz, NH).

[Ac₄(OMe)Neu5Ac-Gab-Ad-Gly₄-NHCH₂]₄C (30). ¹H-NMR spectrum in D₆-DMSO (δ, ppm), matrix: 1.500 (m, 4H, 2 COCH₂CH₂), 2.151 (m, 4H, 2 COCH₂CH₂), 2.688 (br., 2H, CCH₂), 3.720 (x2) and 3.753 (d, 6H, 3 CH₂^{Gly2-4}), 3.841 (d, 2H, CH₂^{Gly1}), 3.864 (d, 2H, ArNHCOCH₂), 7.818 (br. t, 1H, CCH₂NH), 8.045 and 8.084 (x2) (t, 3H, J 6 Hz, NH^{Gly2-4}), 8.102 (t, 1H, J 6 Hz, NHCOCH₂CH₂), 8.555 (t, 1H, J 5.5 Hz, NH^{Gly1}), 9.980 (s, 1H, ArNH). Neu5Acα2-OCH₂C₆H₄ fragment: 1.677, 1.918, 1.975, 2.024 and 2.094 (s, 15H, 5 COCH₃), 1.761 (dd, 1H, J₄ 12.2 Hz, H-3ax), 2.570 (dd, 1H, J_{3ax} 12.5 Hz, J₄ 4.6 Hz, H-3eq), 3.697 (s, 3H, COOCH₃), 3.904 (ddd, 1H, J₄ 10.3 Hz, H-5), 4.028 (dd, 1H, J₈ 6.3 Hz, H-9b), 4.087 (dd, 1H, J₅ 10.7 Hz, H-6), 4.233 (dd, 1H, J_{9b} 12.5 Hz, J₈ 3 Hz, H-9a), 4.320 and 4.643 (d, 2H, J 11.8 Hz, ArCH₂), 4.711 (ddd, 1H, H-4), 5.192 (dd, 1H, J₈ 8.4 Hz, J₆ 2.4 Hz, H-7), 5.341 (ddd, 1H, H-8), 7.214 and 7.555 (d, 2H, J 8.6 Hz, Ar), 7.708 (d, 1H, J₅ 9.6 Hz, NH).

[Ac₄(OMe)Neu5Ac-Gab-Ad-Gly₅-NHCH₂]₄C (31). ¹H-NMR spectrum in D₆-DMSO (δ, ppm): matrix: 1.502 (m, 4H, 2 COCH₂CH₂), 2.147 and 2.159 (m, 4H, 2 COCH₂CH₂), 2.688 (br., 2H, CCH₂), 3.738 (x2) and 3.765 (x2) (m, 8H, 4 CH₂^{Gly2-5}), 3.857 (d, 2H, CH₂^{Gly1}), 3.877 (d, 2H, ArNHCOCH₂), 7.818 (br. t, 1H, CCH₂NH), 8.074 (m, 5H, NHCOCH₂CH₂, NH^{Gly2-5}), 8.551 (t, 1H, J 6 Hz, NH^{Gly1}), 9.968 (s, 1H, ArNH). Neu5Acα2-OCH₂C₆H₄ fragment: 1.677, 1.918, 1.975, 2.024 and 2.094 (s, 15H, 5 COCH₃), 1.761 (dd, 1H, J₄ 12.2 Hz, H-3ax), 2.570 (dd, 1H, J_{3ax} 12.5 Hz, J₄ 4.6 Hz, H-3eq), 3.697 (s, 3H, COOCH₃), 3.904 (ddd, 1H, J₄ 10.3 Hz, H-5), 4.028 (dd, 1H, J₈ 6.3 Hz, H-9b), 4.087 (dd, 1H, J₅ 10.7 Hz, H-6), 4.233 (dd, 1H, J_{9b} 12.5 Hz, J₈ 3 Hz, H-9a), 4.320 and 4.643 (d, 2H, J 11.8 Hz, ArCH₂), 4.711 (ddd, 1H, H-4), 5.192 (dd, 1H, J₈ 8.4 Hz, J₆ 2.4 Hz, H-7), 5.341 (ddd, 1H, H-8), 7.214 and 7.555 (d, 2H, J 8.6 Hz, Ar), 7.708 (d, 1H, J₅ 9.6 Hz, NH).

[Ac₄(OMe)Neu5Ac-Gab-Ad-AC₂-Gly₅-NHCH₂]₄C (32). ¹H-NMR spectrum in D₆-DMSO (δ, ppm), matrix: 1.224, 1.366 and 1.469 (m, 12H, 6 CH₂), 1.502 (m, 4H, 2 COCH₂CH₂), 2.032 and 2.121 (m, 2 COCH₂),), 2.147 and 2.159 (m, 4H, 2 COCH₂CH₂), 2.688 (br., 2H, CCH₂), 3.00 (m, 4H, 2 CH₂NHCO), 3.738 (x2) and 3.765 (x2) (m, 8H, 4 CH₂^{Gly2-5}), 3.857 (d, 2H, CH₂^{Gly1}), 3.877 (d, 2H, ArNHCOCH₂), 7.679 and 7.700 (br. t, 2H, 2 NHCO), 7.818 (br. t, 1H, CCH₂NH), 8.074 (m, 5H, NHCOCH₂CH₂, NH^{Gly2-5}), 8.551 (t, 1H, J 6 Hz, NH^{Gly1}), 9.968 (s, 1H, ArNH). Neu5Acα2-OCH₂C₆H₄ fragment: 1.677, 1.918, 1.975, 2.024 and 2.094 (s, 15H, 5 COCH₃), 1.761 (dd, 1H, J₄ 12.2 Hz, H-3ax), 2.570 (dd, 1H, J_{3ax} 12.5 Hz, J₄ 4.6 Hz, H-3eq), 3.697 (s, 3H, COOCH₃), 3.904 (ddd, 1H, J₄ 10.3 Hz, H-5), 4.028 (dd, 1H, J₈ 6.3 Hz, H-9b), 4.087 (dd, 1H, J₅ 10.7 Hz, H-6), 4.233 (dd, 1H, J_{9b} 12.5 Hz, J₈ 3 Hz, H-9a), 4.320 and 4.643 (d, 2H, J 11.8 Hz, ArCH₂), 4.711 (ddd, 1H, H-4), 5.192 (dd, 1H, J₈ 8.4 Hz, J₆ 2.4 Hz, H-7), 5.341 (ddd, 1H, H-8), 7.214 and 7.555 (d, 2H, J 8.6 Hz, Ar), 7.708 (d, 1H, J₅ 9.6 Hz, NH).

[Ac₄(OMe)Neu5Ac-Gab-Ad-AC₃-Gly₅-NHCH₂]₄C (33). ¹H-NMR spectrum in D₆-DMSO (δ, ppm) is very similar to the spectrum of compound (32) (the signals are in some cases broader and the integrals of the amidocaproic acid groups are correspondingly greater).

[Ac₄(OMe)Neu5Ac-Gab-AC-Ad-Gly₅-NHCH₂]₄C (34). ¹H-NMR spectrum in D₆-DMSO (δ, ppm): matrix: 1.250, 1.382, 1.465 and 1.506 (m, 10H, 5 CH₂), 2.033 and 2.140 (m, 6H, 3 COCH₂), 2.697 (br., 2H, CCH₂), 3.009 (m~q, 2H, J 6.4 Hz, CH₂NHCO), 3.719 (x2) and 3.748 (x2) (m, 8H, 4 CH₂^{Gly2-5}), 3.843 (d, 2H, CH₂^{Gly1}), 3.862 (d, 2H, ArNHCOCH₂), 4.327 and 4.648 (d, 2H, J 11.8 Hz, ArCH₂), 7.216 and 7.555 (d, 2H, J 8 Hz, Ar), 7.698 (t, 1H, NHCO), 7.818 (br. t, 1H, CCH₂NH), 8.039, 8.072, 8.084 (x2), 8.110 (m, 5H, NHCOCH₂CH₂, NH^{Gly2-5}), 8.547 (t, 1H, NH^{Gly1}), 9.970 (s, 1H, ArNH). Neu5Acα2-OCH₂C₆H₄ fragment: 1.677, 1.918, 1.975, 2.024 and 2.094 (s, 15H, 5 COCH₃), 1.761 (dd, 1H, J₄ 12.2 Hz, H-3ax), 2.570 (dd, 1H, J_{3ax} 12.5 Hz, J₄ 4.6 Hz, H-3eq), 3.697 (s, 3H, COOCH₃), 3.904 (ddd, 1H, J₄ 10.3 Hz, H-5), 4.028 (dd, 1H, J₈ 6.3 Hz, H-9b), 4.087 (dd, 1H, J₅ 10.7 Hz, H-6), 4.233 (dd, 1H, J_{9b} 12.5 Hz, J₈ 3 Hz, H-9a), 4.320 and 4.643 (d, 2H, J 11.8 Hz, ArCH₂), 4.711 (ddd, 1H, H-4), 5.192 (dd,

1H, J_8 8.4 Hz, J_6 2.4 Hz, H-7), 5.341 (ddd, 1H, H-8), 7.214 and 7.555 (d, 2H, J 8.6 Hz, Ar), 7.708 (d, 1H, J_5 9.6 Hz, NH).

[Ac₄(OMe)Neu5Ac-Gab-AC₂-Ad-Gly₅-NHCH₂]₄C (35). ¹H-NMR spectrum in D₆-DMSO (δ , ppm): matrix: 1.239, 1.375, 1.465 and 1.509 (m, CH₂), 2.026 and 2.142 (m, COCH₂), 2.711 (br., 2H, CCH₂), 3.003 (m, 4H, 2 CH₂NHCO), 3.718 (x2) and 3.746 (x2) (m, 8H, 4 CH₂^{Gly2-5}), 3.839 (d, 2H, CH₂^{Gly1}), 3.861 (d, 2H, ArNHCOCH₂), 4.329 and 4.649 (d, 2H, J 11.8 Hz, ArCH₂), 7.218 and 7.561 (d, 2H, J 8 Hz, Ar), 7.681 and 7.695 (m, 2H, 2 NHCO), 7.834 (br. t, 1H, CCH₂NH), 8.077, 8.133 (x3), 8.177 (m, 5H, NHCOCH₂CH₂, NH^{Gly2-5}), 8.587 (t, 1H, NH^{Gly1}), 10.01 (s, 1H, ArNH). Neu5Ac α 2-OCH₂C₆H₄ fragment: 1.677, 1.918, 1.975, 2.024 and 2.094 (s, 15H, 5 COCH₃), 1.761 (dd, 1H, J_4 12.2 Hz, H-3ax), 2.570 (dd, 1H, J_{3ax} 12.5 Hz, J_4 4.6 Hz, H-3eq), 3.697 (s, 3H, COOCH₃), 3.904 (ddd, 1H, J_4 10.3 Hz, H-5), 4.028 (dd, 1H, J_8 6.3 Hz, H-9b), 4.087 (dd, 1H, J_5 10.7 Hz, H-6), 4.233 (dd, 1H, J_{9b} 12.5 Hz, J_8 3 Hz, H-9a), 4.320 and 4.643 (d, 2H, J 11.8 Hz, ArCH₂), 4.711 (ddd, 1H, H-4), 5.192 (dd, 1H, J_8 8.4 Hz, J_6 2.4 Hz, H-7), 5.341 (ddd, 1H, H-8), 7.214 and 7.555 (d, 2H, J 8.6 Hz, Ar), 7.708 (d, 1H, J_5 9.6 Hz, NH).

[Ac₄(OMe)Neu5Ac-Gab-AC₃-Ad-Gly₅-NHCH₂]₄C (36). The ¹H-NMR spectrum in D₆-DMSO corresponds very substantially to the spectrum of compound (35), the signals are in some cases broader. Matrix (δ , ppm): 1.239, 1.375, 1.465 and 1.509 (m, CH₂), 2.026 and 2.142 (m, COCH₂), 2.629 (br., 2H, CCH₂), 3.00 (m, 6H, 3 CH₂NHCO), 3.813 (br., 2H, CH₂^{Gly1}), 3.861 (d, 2H, ArNHCOCH₂), 4.329 and 4.649 (d, 2H, J 11.8 Hz, ArCH₂), 7.218 and 7.561 (d, 2H, J 8 Hz, Ar), 7.693 (m, 3H, 3 NHCO), 7.904 (br., 1H, CCH₂NH), 8.083 (x2), 8.158 and 8.215 (x2) (m, 5H, NHCOCH₂CH₂, NH^{Gly2-5}), 8.538 (t, 1H, NH^{Gly1}). Neu5Ac α 2-OCH₂C₆H₄ fragment: 1.677, 1.918, 1.975, 2.024 and 2.094 (s, 15H, 5 COCH₃), 1.761 (dd, 1H, J_4 12.2 Hz, H-3ax), 2.570 (dd, 1H, J_{3ax} 12.5 Hz, J_4 4.6 Hz, H-3eq), 3.697 (s, 3H, COOCH₃), 3.904 (ddd, 1H, J_4 10.3 Hz, H-5), 4.028 (dd, 1H, J_8 6.3 Hz, H-9b), 4.087 (dd, 1H, J_5 10.7 Hz, H-6), 4.233 (dd, 1H, J_{9b} 12.5 Hz, J_8 3 Hz, H-9a), 4.320 and 4.643 (d, 2H, J 11.8 Hz, ArCH₂), 4.711 (ddd, 1H, H-4), 5.192 (dd, 1H, J_8 8.4 Hz, J_6 2.4 Hz, H-7), 5.341 (ddd, 1H, H-8), 7.214 and 7.555 (d, 2H, J 8.6 Hz, Ar), 7.708 (d, 1H, J_5 9.6 Hz, NH).

Table 6. Preparation of protected tetrasialosides (26)-(36) (Example 5)

Methyl ester peracetate	Matrix	Glycoside	Conditions	TLC		Isolation of the products	Yield %
				Rf	Eluant		
[Ac ₄ (OMe)Neu5Ac-Gab-Ad-NHCH ₂ -]4C (26)	(1)		DMF, 24 hours stirring at room temperature	0.21	C	Reaction mixture was concentrated by evaporation <i>in vacuo</i> , LC. CHCl ₃ /MeOH 10:1	57
[Ac ₄ (OMe)Neu5Ac-Gab-Ad-Gly-NHCH ₂ -]4C (27)	(17)	6 mM		0.51	E	Reaction mixture was concentrated by evaporation <i>in vacuo</i> , LC. i-PrOH/EtOAc/H ₂ O 2.5:1	66
[Ac ₄ (OMe)Neu5Ac-Gab-Ad-Gly ₂ -NHCH ₂ -]4C (28)	(18)	(8)		0.25	E	Reaction mixture was concentrated by evaporation <i>in vacuo</i> , LC. acetone/MeOH/H ₂ O 20:1:1→5:1:1	63
[Ac ₄ (OMe)Neu5Ac-Gab-Ad-Gly ₃ -NHCH ₂ -]4C (29)	(19)			0.23	E	Reaction mixture was concentrated by evaporation <i>in vacuo</i> , LC. acetone/MeOH/H ₂ O 30:1:1→10:1:1	33
[Ac ₄ (OMe)Neu5Ac-Gab-Ad-Gly ₄ -NHCH ₂ -]4C (30)	(20)			0.40	G	Reaction mixture was concentrated by evaporation <i>in vacuo</i> , LC. acetone/MeOH/H ₂ O 15:1:1→5:1:1	68
[Ac ₄ (OMe)Neu5Ac-Gab-Ad-Gly ₅ -NHCH ₂ -]4C (31)	(21)		DMSO, 70°C 72 hours	0.18	G	Reaction mixture was concentrated by evaporation <i>in vacuo</i> , LC. acetone/MeOH/H ₂ O 20:1:1→5:1:1	65
[Ac ₄ (OMe)Neu5Ac-Gab-Ad-AC ₂ -Gly ₅ -NHCH ₂ -]4C (32)	(24)	12 mM		0.15	G	Sephadex LH-20, MeCN/H ₂ O 1:1	60
[Ac ₄ (OMe)Neu5Ac-Gab-Ad-AC ₃ -Gly ₅ -NHCH ₂ -]4C (33)	(25)	(8)		0.45	H		57
[Ac ₄ (OMe)Neu5Ac-Gab-AC-Ad-Gly ₅ -NHCH ₂ -]4C (34)	(21)	12 mM (9)		0.16	G	Reaction mixture was lyophilised, LC. eluant G, then i-PrOH/MeOH/EtOAc/H ₂ O 4:3:3	76
[Ac ₄ (OMe)Neu5Ac-Gab-AC ₂ -Ad-Gly ₅ -NHCH ₂ -]4C (35)	(21)	12 mM (10)		0.11	G	Reaction mixture was lyophilised, LC. eluant G, then H	46
[Ac ₄ (OMe)Neu5Ac-Gab-AC ₃ -Ad-Gly ₅ -NHCH ₂ -]4C (36)	(21)	12 mM (11)		0.84	H		11

Example 6.

Preparation of free tetrasialosides

Preparation of [Neu5Ac- α -OCH₂(p-C₆H₄)NHCOCH₂NH-CO(CH₂)₄CO-(NH(CH₂)₅CO)₃-(NHCH₂CO)₅-NHCH₂]-₄C (ammonium salt)

Neu5Ac-Gab-Ad-AC₃-Gly₅-NHCH₂]-₄C (44).

80 μ l of 2N NaOH solution were added to a solution of 10 μ mol of the protected tetrasialoside (33) in 3 ml of absolute MeOH, and after 3 hours 1.5 ml of water and 80 μ l of 2N NaOH solution were again added. The mixture was stirred at room temperature overnight; 80 μ l of AcOH were added and the mixture was evaporated to dryness. The product was obtained by means of gel chromatography over Sephadex G-10 using a 0.05M aqueous NH₄OH solution.

(see Table 7).

Compounds (37)-(43), (45)-(47) were obtained in an analogous manner (see Table 7).

Table 7 (Example 6)

Tetrasialosides	Starting compound	TLC, eluant H, R _f	Aggregate, %*	Yield %
[Neu5Ac-Gab-Ad-NHCH ₂]- ₄ C (37)	(26)	0.80	No self-association	76
[Neu5Ac-Gab-Ad-Gly-NHCH ₂]- ₄ C (38)	(27)	0.82		81
[Neu5Ac-Gab-Ad-Gly ₂ -NHCH ₂]- ₄ C (39)	(28)	0.81		91
[Neu5Ac-Gab-Ad-Gly ₃ -NHCH ₂]- ₄ C (40)	(29)	0.77		90
[Neu5Ac-Gab-Ad-Gly ₄ -NHCH ₂]- ₄ C (41)	(30)	0.75		83
[Neu5Ac-Gab-Ad-Gly ₅ -NHCH ₂]- ₄ C (42)	(31)	0.71		83
[Neu5Ac-Gab-Ad-AC ₂ -Gly ₅ -NHCH ₂]- ₄ C (43)	(32)	Monomer and aggregate are eluted separately;	6	87
[Neu5Ac-Gab-Ad-AC ₃ -Gly ₅ -NHCH ₂]- ₄ C (44)	(33)	monomer: R _f \approx 0.6	54	90
[Neu5Ac-Gab-AC-Ad-Gly ₅ -NHCH ₂]- ₄ C (45)	(34)	aggregate: R _f \approx 0	12	93
[Neu5Ac-Gab-AC ₂ -Ad-Gly ₅ -NHCH ₂]- ₄ C (46)	(35)		92	86
[Neu5Ac-Gab-AC ₃ -Ad-Gly ₅ -NHCH ₂]- ₄ C (47)	(36)		96	89

*Determined by means of gel permeation chromatography

[Neu5Ac-Gab-Ad-NHCH₂]-₄C (37). ¹H-NMR spectrum in D₂O (δ, ppm): matrix: 1.633 (m, 4H, COCH₂CH₂), 2.293 and 2.358 (m, 4H, 2 COCH₂CH₂), 2.943 (s, 2H, CCH₂), 4.003 (s, 2H, ArNHCOCH₂), 4.493 and 4.718 (d, 2H, J 11 Hz, ArCH₂), 7.388 (m, 4H, Ar). Neu5Acα fragment : 1.680 (dd, 1H, J₄ 12 Hz, H-3ax), 2.036 (s, 3H, NAc), 2.778 (dd, 1H, J_{3ax} 12.5 Hz, J₄ 4.6 Hz, H-3eq), 3.598 (dd, 1H, J₈ 9 Hz, H-7), 3.636 (dd, 1H, J₈ 6 Hz, H-9b), 3.695 (ddd, 1H, J₅ 9.8 Hz, H-4), 3.728 (dd, 1H, J₇ 1.5 Hz, J₅ 10.2 Hz, H-6), 3.782 (ddd, 1H, H-8), 3.822 (dd, 1H, H-5), 3.846, (dd, 1H, J_{9b} 12 Hz, J₈ 2.3 Hz, H-9a).

[Neu5Ac-Gab-Ad-Gly-NHCH₂]-₄C (38). ¹H-NMR spectrum in D₂O (δ, ppm): matrix: 1.622 (m, 4H, COCH₂CH₂), 2.340 and 2.382 (m, 4H, 2 COCH₂CH₂), 2.810 (s, 2H, CCH₂), 3.847 (s, 2H, CH₂^{Gly}), 4.016 (s, 2H, ArNHCOCH₂), 4.492 and 4.707 (d, 2H, J 11 Hz, ArCH₂), 7.402 (m, 4H, Ar). Neu5Acα fragment : 1.680 (dd, 1H, J₄ 12 Hz, H-3ax), 2.036 (s, 3H, NAc), 2.778 (dd, 1H, J_{3ax} 12.5 Hz, J₄ 4.6 Hz, H-3eq), 3.598 (dd, 1H, J₈ 9 Hz, H-7), 3.636 (dd, 1H, J₈ 6 Hz, H-9b), 3.695 (ddd, 1H, J₅ 9.8 Hz, H-4), 3.728 (dd, 1H, J₇ 1.5 Hz, J₅ 10.2 Hz, H-6), 3.782 (ddd, 1H, H-8), 3.822 (dd, 1H, H-5), 3.846, (dd, 1H, J_{9b} 12 Hz, J₈ 2.3 Hz, H-9a).

[Neu5Ac-Gab-Ad-Gly₂-NHCH₂]-₄C (39). ¹H-NMR spectrum in D₂O (δ, ppm): matrix: 1.626 (m, 4H, COCH₂CH₂), 2.341 (m, 4H, 2 COCH₂CH₂), 2.831 (s, 2H, CCH₂), 3.894 and 3.991 (s, 4H, 2 CH₂^{Gly1,2}), 4.022 (s, 2H, ArNHCOCH₂), 4.492 and 4.719 (d, 2H, J 11 Hz, ArCH₂), 7.402 (m, 4H, Ar). Neu5Acα fragment : 1.680 (dd, 1H, J₄ 12 Hz, H-3ax), 2.036 (s, 3H, NAc), 2.778 (dd, 1H, J_{3ax} 12.5 Hz, J₄ 4.6 Hz, H-3eq), 3.598 (dd, 1H, J₈ 9 Hz, H-7), 3.636 (dd, 1H, J₈ 6 Hz, H-9b), 3.695 (ddd, 1H, J₅ 9.8 Hz, H-4), 3.728 (dd, 1H, J₇ 1.5 Hz, J₅ 10.2 Hz, H-6), 3.782 (ddd, 1H, H-8), 3.822 (dd, 1H, H-5), 3.846, (dd, 1H, J_{9b} 12 Hz, J₈ 2.3 Hz, H-9a).

[Neu5Ac-Gab-Ad-Gly₃-NHCH₂]-₄C (40). ¹H-NMR spectrum in D₂O (δ, ppm): matrix: 1.631 (m, 4H, COCH₂CH₂), 2.344 (m, 4H, 2 COCH₂CH₂), 2.857 (s, 2H, CCH₂), 3.912, 3.931 and 4.024 (s, 6H, 3 CH₂^{Gly1-3}), 4.029 (s, 2H, ArNHCOCH₂), 4.500 and 4.725 (d, 2H, J 11 Hz, ArCH₂), 7.408 (m, 4H, Ar). Neu5Acα fragment : 1.680 (dd, 1H, J₄ 12 Hz, H-3ax), 2.036 (s, 3H, NAc), 2.778 (dd, 1H, J_{3ax} 12.5 Hz, J₄ 4.6 Hz, H-3eq), 3.598 (dd, 1H, J₈ 9 Hz, H-7), 3.636 (dd, 1H, J₈ 6 Hz, H-9b), 3.695 (ddd, 1H, J₅ 9.8 Hz, H-4), 3.728 (dd, 1H, J₇ 1.5 Hz, J₅ 10.2 Hz, H-6), 3.782 (ddd, 1H, H-8), 3.822 (dd, 1H, H-5), 3.846, (dd, 1H, J_{9b} 12 Hz, J₈ 2.3 Hz, H-9a).

[Neu5Ac-Gab-Ad-Gly₄-NHCH₂]-₄C (41). ¹H-NMR spectrum in D₂O (δ, ppm): matrix: 1.636 (m, 4H, COCH₂CH₂), 2.350 (m, 4H, 2 COCH₂CH₂), 2.864 (s, 2H, CCH₂), 3.912, 3.934, 3.968 and 4.025 (s, 8H, 4 CH₂^{Gly1-4}), 4.032 (s, 2H, ArNHCOCH₂), 4.497 and 4.725 (d, 2H, J 11 Hz, ArCH₂), 7.408 (m, 4H, Ar). Neu5Acα fragment : 1.680 (dd, 1H, J₄ 12 Hz, H-3ax), 2.036 (s, 3H, NAc), 2.778 (dd, 1H, J_{3ax} 12.5 Hz, J₄ 4.6 Hz, H-3eq), 3.598 (dd, 1H, J₈ 9 Hz, H-7), 3.636 (dd, 1H, J₈ 6 Hz, H-9b), 3.695 (ddd, 1H, J₅ 9.8 Hz, H-4), 3.728 (dd, 1H, J₇ 1.5 Hz, J₅ 10.2 Hz, H-6), 3.782 (ddd, 1H, H-8), 3.822 (dd, 1H, H-5), 3.846, (dd, 1H, J_{9b} 12 Hz, J₈ 2.3 Hz, H-9a).

[Neu5Ac-Gab-Ad-Gly₅-NHCH₂]-₄C (42). ¹H-NMR spectrum in D₂O (δ, ppm): matrix: 1.638 (m, 4H, COCH₂CH₂), 2.355 (m, 4H, 2 COCH₂CH₂), 2.878 (s, 2H, CCH₂), 3.921, 3.933, 3.974 (x2) and 4.032 (s, 10H, 5 CH₂^{Gly1-5}), 4.036 (s, 2H, ArNHCOCH₂), 4.502 and 4.724 (d, 2H, J 11 Hz, ArCH₂), 7.410 (m, 4H, Ar). Neu5Acα fragment : 1.680 (dd, 1H, J₄ 12 Hz, H-3ax), 2.036 (s, 3H, NAc), 2.778 (dd, 1H, J_{3ax} 12.5 Hz, J₄ 4.6 Hz, H-3eq), 3.598 (dd, 1H, J₈ 9 Hz, H-7), 3.636 (dd, 1H, J₈ 6 Hz, H-9b), 3.695 (ddd, 1H, J₅ 9.8 Hz, H-4), 3.728 (dd, 1H, J₇ 1.5 Hz, J₅ 10.2 Hz, H-6), 3.782 (ddd, 1H, H-8), 3.822 (dd, 1H, H-5), 3.846, (dd, 1H, J_{9b} 12 Hz, J₈ 2.3 Hz, H-9a).

[Neu5Ac-Gab-Ad-AC₂-Gly₅-NHCH₂]-₄C (43). ¹H-NMR spectrum in D₂O (δ, ppm): matrix: 1.286, 1.476 and 1.567 (m, 12H, 6 CH₂), 1.623 (m, 4H, COCH₂CH₂CH₂CH₂CO), 2.179 (t, 2H, J 7.4 Hz, CH₂CO), 2.245 and 2.367 (m, 4H, COCH₂CH₂CH₂CH₂CO), 2.299 (t, 2H, J 7.4 Hz, CH₂CO), 2.882 (s, 2H, CCH₂), 3.133 (m, 4H, 2 CH₂N), 3.928, 3.940, 3.987 (x2) and 4.043 (x2) (s, 12H, 6 COCH₂N), 4.502 and 4.730 (d, 2H, J 11 Hz, ArCH₂), 7.418 (m, 4H, Ar). Neu5Acα fragment : 1.680 (dd, 1H, J₄ 12 Hz, H-3ax), 2.036 (s, 3H, NAc), 2.778 (dd, 1H, J_{3ax} 12.5 Hz, J₄ 4.6 Hz, H-3eq), 3.598 (dd, 1H, J₈ 9 Hz, H-7), 3.636 (dd, 1H, J₈ 6 Hz, H-9b), 3.695 (ddd, 1H, J₅ 9.8 Hz, H-4), 3.728 (dd, 1H, J₇ 1.5 Hz, J₅ 10.2 Hz, H-6), 3.782 (ddd, 1H, H-8), 3.822 (dd, 1H, H-5), 3.846, (dd, 1H, J_{9b} 12 Hz, J₈ 2.3 Hz, H-9a).

Aggregate **[Neu5Ac-Gab-Ad-AC₃-Gly₅-NHCH₂]-₄C (44).** ¹H-NMR spectrum in D₂O is very similar to the spectrum of compound (43), matrix (δ, ppm): 1.283, 1.476, 1.570 (m, 18H, 9 CH₂), 2.178 and 2.189 (t, 2x2H, J 7.4 Hz, 2 CH₂CO), 2.301 (t, 2H, J 7.4 Hz, CH₂CO), 3.135 (m, 6H, 3 CH₂N), 3.928, 3.940, 3.987 (x2) and 4.043 (x2) (s, 12H, 6 COCH₂N), 4.502 and 4.730 (d, 2H, J 11 Hz, ArCH₂), 7.418 (m, 4H, Ar).

Neu5Acα fragment : 1.680 (dd, 1H, J₄ 12 Hz, H-3ax), 2.036 (s, 3H, NAc), 2.778 (dd, 1H, J_{3ax} 12.5 Hz, J₄ 4.6 Hz, H-3eq), 3.598 (dd, 1H, J₈ 9 Hz, H-7), 3.636 (dd, 1H, J₈ 6 Hz, H-9b), 3.695 (ddd, 1H, J₅ 9.8 Hz, H-4), 3.728 (dd, 1H, J₇ 1.5 Hz, J₅ 10.2 Hz, H-6), 3.782 (ddd, 1H, H-8), 3.822 (dd, 1H, H-5), 3.846, (dd, 1H, J_{9b} 12 Hz, J₈ 2.3 Hz, H-9a).

[Neu5Ac-Gab-AC-Ad-Gly₅-NHCH₂]-₄C (45). ¹H-NMR spectrum in D₂O (δ, ppm): matrix: 1.334 (m, 2H, CH₂), 1.504 (m, 2H, CH₂CH₂NH), 1.569 (m, 4H, COCH₂CH₂CH₂CH₂CO), 1.625 (m, 2H, CH₂CH₂CO), 2.207 and 2.313 (m, 4H, COCH₂CH₂CH₂CH₂CO), 2.344 (t, 2H, J 7 Hz, CH₂CO), 2.885 (s, 2H, CCH₂), 3.156 (t, 2H, J 7.4 Hz, CH₂N), 3.928, 3.942, 3.979, 3.984, 4.037 and 4.042 (s, 12H, 6 COCH₂N), 4.506 and 4.729 (d, 2H, J 11 Hz, ArCH₂), 7.420 (m, 4H, Ar). Neu5Acα fragment : 1.680 (dd, 1H, J₄ 12 Hz, H-3ax), 2.036 (s, 3H, NAc), 2.778 (dd, 1H, J_{3ax} 12.5 Hz, J₄ 4.6 Hz, H-3eq), 3.598 (dd, 1H, J₈ 9 Hz, H-7), 3.636 (dd, 1H, J₈ 6 Hz, H-9b), 3.695 (ddd, 1H, J₅ 9.8 Hz, H-4), 3.728 (dd, 1H, J₇ 1.5 Hz, J₅ 10.2 Hz, H-6), 3.782 (ddd, 1H, H-8), 3.822 (dd, 1H, H-5), 3.846, (dd, 1H, J_{9b} 12 Hz, J₈ 2.3 Hz, H-9a).

Aggregate **[Neu5Ac-Gab-AC₂-Ad-Gly₅-NHCH₂]₄C (46)**. ¹H-NMR spectrum in D₂O (δ, ppm): matrix: 1.268, 1.504 and 1.630 (m, 12H, 6 CH₂), 1.572 (m, 4H, COCH₂CH₂CH₂CH₂CO), 2.185 (t, 2H, J 7 Hz, CH₂CO), 2.212 and 2.315 (m, 4H, COCH₂CH₂CH₂CH₂CO), 2.349 (t, 2H, J 7.4 Hz, CH₂CO), 2.898 (s, 2H, CCH₂), 3.130 and 3.158 (t, 2x2H, J 7.4 Hz, 2 CH₂N), 3.934, 3.945, 3.987 (x2), 4.039 and 4.045 (s, 12H, 6 COCH₂N), 4.509 and 4.725 (d, 2H, J 11 Hz, ArCH₂), 7.422 (m, 4H, Ar). Neu5Acα fragment : 1.680 (dd, 1H, J₄ 12 Hz, H-3ax), 2.036 (s, 3H, NAc), 2.778 (dd, 1H, J_{3ax} 12.5 Hz, J₄ 4.6 Hz, H-3eq), 3.598 (dd, 1H, J₈ 9 Hz, H-7), 3.636 (dd, 1H, J₈ 6 Hz, H-9b), 3.695 (ddd, 1H, J₅ 9.8 Hz, H-4), 3.728 (dd, 1H, J₇ 1.5 Hz, J₅ 10.2 Hz, H-6), 3.782 (ddd, 1H, H-8), 3.822 (dd, 1H, H-5), 3.846, (dd, 1H, J_{9b} 12 Hz, J₈ 2.3 Hz, H-9a).

Aggregate **[Neu5Ac-Gab-AC₃-Ad-Gly₅-NHCH₂]₄C (47)**. The ¹H-NMR spectrum in D₂O is very similar to the spectrum of compound (46), the signals are in some cases broader. Matrix (δ, ppm): 1.276, 1.461 and 1.630 (m, 18H, 9 CH₂), 2.186 (t, 2x2H, J 7 Hz, 2 CH₂CO), 2.349 (t, 2H, J 7.4 Hz, CH₂CO), 3.132 (m, 6H, 3 CH₂N), 3.934, 3.945, 3.987 (x2), 4.039 and 4.045 (s, 12H, 6 COCH₂N), 4.509 and 4.725 (d, 2H, J 11 Hz, ArCH₂), 7.422 (m, 4H, Ar). Neu5Acα fragment : 1.680 (dd, 1H, J₄ 12 Hz, H-3ax), 2.036 (s, 3H, NAc), 2.778 (dd, 1H, J_{3ax} 12.5 Hz, J₄ 4.6 Hz, H-3eq), 3.598 (dd, 1H, J₈ 9 Hz, H-7), 3.636 (dd, 1H, J₈ 6 Hz, H-9b), 3.695 (ddd, 1H, J₅ 9.8 Hz, H-4), 3.728 (dd, 1H, J₇ 1.5 Hz, J₅ 10.2 Hz, H-6), 3.782 (ddd, 1H, H-8), 3.822 (dd, 1H, H-5), 3.846, (dd, 1H, J_{9b} 12 Hz, J₈ 2.3 Hz, H-9a).

Example 7.

Preparation of the aggregate **{[Neu5Acα-OCH₂(p-C₆H₄)NHCOCH₂NH-CO(CH₂)₄CO-(NHCH₂CO)₇-NHCH₂]₄C}_x (ammonium salt)**

{[Neu5Ac-Gab-Ad-Gly₇-NHCH₂]₄C}_x (48).

18.8 mg (26 μmol) of the lyophilised compound (15) are added to 6.1 mg (3.25 μmol) of tetrahydrochloride (22a), prepared as described in Example 4, in 0.5 ml of water. The pH of the reaction mixture was adjusted to pH = 8 with 1M NaHCO₃ solution. The reaction solution was stirred at room temperature for 3 days, the pH being maintained at 8 by the addition of 1M NaHCO₃ solution. The reaction mixture was separated over a Sephadex LH-20 column with a 0.05M aqueous NH₄OH solution. After concentration and drying *in vacuo*, 9.6 mg of product (48) were obtained, corresponding to a yield of 71%.

¹H-NMR spectrum (D₂O, δ, ppm): matrix: 1.638 (m, 4H, COCH₂CH₂), 2.358 (m, 4H, 2 COCH₂CH₂), 2.878 (s, 2H, CCH₂), 3.918, 3.938, 3.978 (x4) and 4.034 (s, 14H, 7 CH₂^{Gly1-7}), 4.037 (s, 2H, ArNHCOCH₂), 4.498 and 4.718 (d, 2H, J 11 Hz, ArCH₂), 7.408 (m, 4H, Ar). Neu5Acα fragment : 1.680 (dd, 1H, J₄ 12 Hz, H-3ax), 2.036 (s, 3H, NAc), 2.778 (dd, 1H, J_{3ax}

12.5 Hz, J_4 4.6 Hz, H-3eq), 3.598 (dd, 1H, J_8 9 Hz, H-7), 3.636 (dd, 1H, J_8 6 Hz, H-9b), 3.695 (ddd, 1H, J_5 9.8 Hz, H-4), 3.728 (dd, 1H, J_7 1.5 Hz, J_5 10.2 Hz, H-6), 3.782 (ddd, 1H, H-8), 3.822 (dd, 1H, H-5), 3.846, (dd, 1H, J_{9b} 12 Hz, J_8 2.3 Hz, H-9a).

Example 8.

Preparation of aggregates

Preparation of $\{Gal\alpha 1-3Gal\beta 1-O(CH_2)_3NH-CO(CH_2)_4CO-(NH(CH_2)_5CO)_3-(NHCH_2CO)_5-NHCH_2-[4C]\}_x$

$\{[B_{\alpha 1}-Ap-Ad-AC_3-Gly_5-NHCH_2-[4C]]_x$ (**49**).

15.6 mg of (**16**) and 5 μ l of Et₃N were added to a suspension von 5.6 mg (2 μ mol) of tetrahydrochloride (**25a**), prepared as described in Example 4, in 0.5 ml of DMSO. The reaction solution was stirred at 40°C for 3 days. After the addition of 0.2 ml of conc. NH₄OH solution, the reaction mixture was stirred for 30 minutes and separated over a Sephadex LH-20 column with MeCN/H₂O 1:1. After concentration and drying *in vacuo*, 6.4 mg of product (**49**) were obtained, corresponding to a yield of 69%.

¹H-NMR spectrum (D₂O/CD₃OD 2:1, δ , ppm): 1.374, 1.562 and 1.645 (m, CH₂), 1.883 (m, 2H, OCH₂CH₂CH₂N), 2.265 (t, 4H, J 7.5 Hz, 2 CH₂CO), 2.292 (m, 4H, 2 CH₂CO), 2.377 (t, 2H, J 7.5 Hz, CH₂CO), 2.955 (br. s, CCH₂), 3.213 (t, 6H, 3 CH₂N), 3.348 (m, 2H, OCH₂CH₂CH₂N), 3.697 (dd, 1H, H-2 Gal β), 3.756 (m, OCH₂CH₂CH₂N), 3.910 (dd, 1H, J_3 10 Hz, H-2 Gal α), 4.00, 4.046 and 4.097 (s, 10H, 5 COCH₂N), 4.205 (d, 1H, J_3 3 Hz, H-4 Gal β), 4.255 (m, 1H, H-5 Gal α), 4.462 (d, 1H, J_2 8 Hz, H-1 Gal β), 5.184 (d, 1H, J_2 4 Hz, H-1 Gal α).

Preparation of $\{[Neu5Ac\alpha 2-3Gal\beta 1-4Glc\beta 1-NHCOCH_2NH-CO(CH_2)_4CO-(NHCH_2CO)_5-NHCH_2-[4C]]_x$

$\{[3^{\prime}SL-NHCOCH_2NH-Ad-Gly_5-NHCH_2-[4C]]_x$ (**50**)

was prepared starting from (**21a**) and (**14**) analogously to compound (**49**).

TLC: R_f 0.52 (methanol/acetonitrile/water 6:6:3). Yield 65%.

¹H-NMR spectrum (D₂O, δ , ppm): 1.622 (m, 4H, CH₂CH₂CH₂CO), 1.797 (dd, 1H, J_4 12 Hz, H-3_{ax} Neu5Ac), 2.017 (s, 3H, COCH₃), 2.342 (m, 4H, 2 CH₂CO), 2.744 (dd, 1H, J_{3ax} 12.5 Hz, J_4 4.6 Hz, H-3_{eq} Neu5Ac), 2.895 (br. s, CCH₂), 3.452 (dd, 1H, H-2 Glc β), 3.568 (dd, 1H, J_3 10 Hz, H-2 Gal β), 3.954, 3.992 and 4.041 (s, 12H, 6 COCH₂N), 4.105 (dd, 1H, J_2 10 Hz, J_4 3 Hz, H-3 Gal β), 4.523 (d, 1H, J_2 8 Hz, H-1 Gal β), 5.005 (d, 1H, J_2 9 Hz, H-1 Glc β).

Preparation of $\{[Neu5Ac\alpha2-3Gal\beta1-4Glc\beta1-NHCOCH_2NH-CO(CH_2)_4CO-(NHCH_2CO)]_7-NHCH_2-[4C]_x\}$

$\{[3'SL-NHCOCH_2NH-Ad-Gly_7-NHCH_2-]_4C\}_x$ (51)

was prepared analogously to compound (48) starting from (22a) and (14). Yield 78%.

1H -NMR spectrum (D_2O , δ , ppm): 1.622 (m, 4H, $CH_2CH_2CH_2CO$), 1.797 (dd, 1H, J_4 12 Hz, H-3_{ax} Neu5Ac), 2.017 (s, 3H, $COCH_3$), 2.342 (m, 4H, 2 CH_2CO), 2.744 (dd, 1H, J_{3ax} 12.5 Hz, J_4 4.6 Hz, H-3_{eq} Neu5Ac), 2.895 (br. s, CCH_2), 3.452 (dd, 1H, H-2 Glc β), 3.568 (dd, 1H, J_3 10 Hz, H-2 Gal β), 3.954, 3.992 and 4.041 (s, 16H, 8 $COCH_2N$), 4.105 (dd, 1H, J_2 10 Hz, J_4 3 Hz, H-3 Gal β), 4.523 (d, 1H, J_2 8 Hz, H-1 Gal β), 5.005 (d, 1H, J_2 9 Hz, H-1 Glc β).

Example 9

Induction of self-association of $[HCl-H-Gly_7-NHCH_2-]_4C$ (22a).

The investigation into the light scattering of a 50mM solution of compound (22a) in water was carried out using a Spectra-Physics 164 argon laser (plasma lines $\lambda=528.7$ and 611.5 nm), the scattering was measured at an angle of 90° to the incident light beam. The particle size thereby determined was <2.5 nm. 50 μ l of a 0.8M $NaHCO_3$ solution were added to the resulting solution. The light scattering was measured, as described above, the average particle size thereby determined was 200-400 nm.

50 μ l of a 0.8M HCl was added to the resulting solution, and the sample was investigated by means of light scattering, as described above. The particle size thereby determined was < 2.5 nm.

Example 10

Inhibition of the viral cell adhesion of influenza viruses

The specific binding constants of the inhibitor virus complexes were determined by means of a fetuin binding assay, as described in the literature (US Patent 5,571,836, 1996; PCT WO 98/14215).

Table 8, Example 10
Influenza virus A/NIB/44/90M H3N2

Inhibitor	Compound No.	K _d , μM
Neu5Acα-OBn		100
[Neu5Ac-Gab-Ad-Gly _n -NHCH ₂] ₄ C (n=0-5)	(38) - (42)	~50
[Neu5Ac-Gab-Ad-Gly ₇ -NHCH ₂] ₄ C	(48)	0.1
[Neu5Ac-Ap-Ad-Gly _n -NHCH ₂] ₄ C (n=0-3)		200
[Neu5Ac-Gab-AC-Ad-Gly ₅ -NHCH ₂] ₄ C	(45)	7
[Neu5Ac-Gab-AC ₂ -Ad-Gly ₅ -NHCH ₂] ₄ C	(46)	0.3
[Neu5Ac-Gab-AC ₃ -Ad-Gly ₅ -NHCH ₂] ₄ C	(47)	0.1
[Neu5Ac-Gab-Ad-AC ₂ -Gly ₅ -NHCH ₂] ₄ C	(43)	0.1
[Neu5Ac-Gab-Ad-AC ₃ -Gly ₅ -NHCH ₂] ₄ C	(44)	0.04
Influenza virus A/Duck/Alberta/60/67 H12N5		
3'SL		20
[3'SL-NHCOCH ₂ NH-Ad-Gly ₅ -NHCH ₂] ₄ C	(50)	1
[3'SL-NHCOCH ₂ NH-Ad-Gly ₇ -NHCH ₂] ₄ C	(51)	0.1

Example 11

Inhibition of the complement-dependent cytotoxicity of human blood sera with respect to PK 15 cells as a result of the aggregate $\{[B_{df}-Ap-Ad-AC_3-Gly_5-NHCH_2]_4C\}_x$ (49)

Serial dilutions of the B disaccharide Galα1-3Gal and of the aggregate $\{[B_{df}-Ap-Ad-AC_3-Gly_5-NHCH_2]_4C\}_x$ (49) with human blood serum were incubated at 4°C overnight, and the inhibition of the cytotoxicity was demonstrated, as described in the literature (R.Rieben, E.von Allmen, E.Y.Korchagina, U.E.Nydegger, F.A.Neethling, M.Kujundzic, E.Koren, N.V.Bovin, D.K.C.Cooper, *Xenotransplantation*, 2, 98, 1995). After the addition of the complement constituents in the form of 10% rabbit serum (Sigma), the samples were incubated for 10 minutes with PK15 cells grown on Terasaki plates. The cells were then washed and stained using a cytotoxicity kit ("live/dead" viability/cytotoxicity kit, Molecular Probes, Eugene, OR, USA). By measuring the fluorescence intensities, the live/dead proportions were determined. The inhibition of cytotoxicity was calculated by comparison with a serum sample to which no inhibitor had been added. In the case of the following concentrations (calculated as molar concentration of the B disaccharide units), 50 % inhibition of cytotoxicity was achieved:

Galα1-3Gal (B disaccharide)	200 μM
$\{[B_{df}-Ap-Ad-AC_3-Gly_5-NHCH_2]_4C\}_x$ aggregate (49)	0.5 μM

Example 12

The divalent matrices of the formula $[\text{HCl-H-Gly}_n\text{-NHCH}_2\text{CH}_2\text{-}]_2$ ($n = 2, 4$) were prepared starting from 1,4-diaminobutane analogously to the synthesis in Example 4.

Preparation of bis-1,4-(hexaglycylamido)-butane $[\text{HCl-H-Gly}_6\text{-NHCH}_2\text{CH}_2\text{-}]_2$ (**52**).

48 mg of BocGlyGlyNOS (146 μmol) and 0.1 ml of Et_3N were added to a solution of 30 mg of the compound $[\text{HCl-H-Gly}_4\text{-NHCH}_2\text{CH}_2\text{-}]_2$ (48.6 μmol) in 0.5 ml of DMSO. The reaction mixture was stirred at room temperature for 24 hours, a precipitate being formed. After the addition of 1 ml of water, the precipitate was separated off by centrifugation, suspended three times in 1 ml of MeOH each time and again centrifuged. After drying *in vacuo*, 0.5 ml of trifluoroacetic acid was added to the residue. After two hours, 3 ml of toluene were twice added and the solution concentrated. The residue was dissolved in water and, after the addition of 0.1 ml of a 2M HCl solution, evaporated to dryness. The product was obtained by means of gel chromatography over a Sephadex LH-20 column (1 \times 30 cm) with a 50 % aqueous acetonitrile solution. After freeze-drying of the product fraction, 26 mg (63 %) of compound (**52**) were obtained.

$^1\text{H-NMR}$ spectrum in D_2O (δ , ppm): 1.455 (m, 4H, $\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2$), 3.172 (m, 4H, $2\text{CH}_2\text{N}$), 3.856, 3.872, 3.947, 3.960, 3.975 and 4.028 (s, 2H, COCH_2N).

The aggregate $\{[\text{Neu5Ac}\alpha\text{-OCH}_2(p\text{-C}_6\text{H}_4)\text{NHCOCH}_2\text{NH-CO}(\text{CH}_2)_4\text{CO-(NHCH}_2\text{CO)}_6\text{-NHCH}_2\text{CH}_2\text{-}]_x, (\text{ammonium salt}) \{[\text{Neu5Ac-Gab-Ad-Gly}_6\text{-NHCH}_2\text{CH}_2\text{-}]_x\}$ (**53**) was prepared analogously to compound (**48**) in Example 7.

Yield 72 %

$^1\text{H-NMR}$ spectrum in D_2O (δ , ppm): matrix: 1.470 (m, 4H, $\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2$), 1.649 (m, 4H, COCH_2CH_2), 2.363 (m, 4H, $2\text{COCH}_2\text{CH}_2$), 3.181 (m, 4H, $2\text{CH}_2\text{N}$), 3.869, 3.941, 3.962, 3.977 (x3) and 4.045 (s, 2H, COCH_2N), 4.505 and 4.727 (d, 2H, J 11 Hz, ArCH_2), 7.415 (m, 4H, Ar). Neu5Ac α fragment : 1.680 (dd, 1H, J_4 12 Hz, H-3ax), 2.086 (s, 3H, NAc), 2.778 (dd, 1H, $J_{3\text{ax}}$ 12.5 Hz, J_4 4.6 Hz, H-3eq), 3.598 (dd, 1H, J_8 9 Hz, H-7), 3.636 (dd, 1H, J_8 6 Hz, H-9b), 3.695 (ddd, 1H, J_5 9.8 Hz, H-4), 3.728 (dd, 1H, J_7 1.5 Hz, J_5 10.2 Hz, H-6), 3.782 (ddd, 1H, H-8), 3.822 (dd, 1H, H-5), 3.846 (dd, 1H, J_{9b} 12 Hz, J_8 2.3 Hz, H-9a).

Example 13

Preparation of NeuAc α 2-6Gal β 1-4GlcNAc β -O(CH₂)₃NH-CO(CH₂)₄COO(p-C₆H₄NO₂) 6'SLN-Ap-Ad-ONp (52).

A solution of 65 mg (195 μ mol) of di-(4-nitrophenyl) adipate (3) in 300 μ l of DMF was added to a solution of 28 mg (38 μ mol) of the compound 6'SLN-O(CH₂)₃NH₂ in 400 μ l of DMSO. The mixture was stirred at 20°C for 16 hours. After the addition of 5 ml of H₂O and 0.1 ml of AcOH, the excess (3) was filtered off. The filtrate was concentrated to a small volume of about 1 ml and separated by means of gel permeation chromatography over Sephadex LH-20 (MeCN /H₂O/AcOH 1:1:0.005).

Yield (52) - 71%. TLC: R_f 0.46 (i-PrOH / acetone /H₂O 4:3:2).

¹H-NMR spectrum (D₂O, δ , ppm): 1.641 (m, 6H, 2 COCH₂CH₂ and OCH₂CH₂), 1.674 (dd, 1H, H-3-ax Neu5Ac), 1.930 and 1.958 (s, 2x3H, 2 COCH₃, Neu5Ac and GlcNAc), 2.218 (t, 2H, NCOCH₂), 2.559 (dd, 1H, J_{3ax}, 13Hz, J₄ 4.7 Hz, H-3eq Neu5Ac), 2.646 (m, 2H, CH₂COOAr), 3.090 and 3.190 (m, 2x1H, NCH₂), 3.42-3.94 (21H, overlapping of the carbohydrate signals and OCH₂), 4.328 (d, 1H, J₂ 8 Hz, H-1 Gal), 4.419 (d, 1H, J₂ 8 Hz, H-1 GlcNAc), 7.291 and 8.256 (d, 2x2H, J 8.3 Hz, Ar).

Preparation of [6'SLN-Ap-Ad-Gly₇-NHCH₂]₄C (53)

15 mg (16.2 μ mol) of the compound NeuAc α 2-6Gal β 1-4GlcNAc β -O(CH₂)₃NH-CO(CH₂)₄COO(p-C₆H₄NO₂) (52) were added to a solution of 5 mg (2.7 μ mol) of the tetrahydrochloride [HCl Gly₇-NHCH₂]₄C (22a) in 500 μ l of H₂O.

The pH value of the resulting solution was adjusted to pH~8 by the dropwise addition of 1M NaHCO₃. The reaction mixture was stirred at room temperature for 3 days and separated by means of gel permeation chromatography (G10, 0.05M NH₃).

Yield (53) 34%, TLC: R_f~0 (i-PrOH /acetone/H₂O 4:3:2).

¹H-NMR spectrum (D₂O, δ , ppm): matrix: 1.628 (m, 4H, COCH₂CH₂), 1.789 (m, 2H, OCH₂CH₂), 2.275 and 2.373 (m, 2x2H, 2 COCH₂CH₂), 2.935 (s, 2H, CCH₂), 3.197 and 3.279 (m, 2x1H, NCH₂), 3.971, 3.990, 4.026 (x3) and 4.077 (x2) (s, 14H, 7 CH₂^{Gly1-7}). Carbohydrate signals: 1.730 (dd, 1H, H-3ax Neu5Ac), 2.049 and 2.078 (s, 2x3H, 2 COCH₃, Neu5Ac and GlcNAc), 2.693 (dd, 1H, J_{3ax} 12.4 Hz, J₄ 4.6 Hz, H-3eq Neu5Ac), 3.54-3.96 (21 H, overlapping of the carbohydrate signals and OCH₂), 4.468 (d, 1H, J₂ 8Hz, H-1 Gal), 4.562 (d, 1H, J₂ 8 Hz, H-1 GlcNAc).

The compound **[6'SLN-Ap-Ad-AC₂-Gly₅-NHCH₂]₄C (54)** was prepared in an analogous manner starting from the tetrahydrochloride **[HCl·H-AC₂-Gly₅-NHCH₂]₄C (24a)** and **NeuAcα2-6Galβ1-4GlcNAcβ-O(CH₂)₃NH-CO(CH₂)₄COO(p-C₆H₄NO₂) (52)**.

Yield (54) - 63%. TLC: R_f~0 (i-PrOH/acetone/H₂O 4:3:2).

¹H-NMR spectrum in D₂O (δ, ppm): matrix: 1.341, 1.524 and 1.631 (m, 12H, 6 CH₂), 1.599 (m, 4H, COCH₂CH₂CH₂CH₂CO), 1.785 (m, 2H, OCH₂CH₂), 2.238 (t, 2H, J 7.4 Hz, CH₂CO), 2.260 (m, 4H, COCH₂CH₂CH₂CH₂CO), 2.349 (t, 2H, J 7.5 Hz, CH₂CO), 2.929 (s, 2H, CCH₂), 3.182 (broad t, 4H, J 6.6 Hz, 2 CH₂N), 3.195 and 3.275 (m, 2x1H, NCH₂), 3.979, 4.022 (x3) and 4.073 (s, 10H, 5 COCH₂N). Carbohydrate signals: see (53).

Table 9, Example 13

Inhibition of the viral time-adhesion of influenza viruses; strain A/NIB/H1N1/89M, FBI text [see Table 1], 6'SLN as reference compound.

Inhibitor	Compound No.	Relative activity
6'SLN		1
[Neu5Ac-Gab-Ad-Gly ₇ -NHCH ₂] ₄ C	(48)	< 0.2
[6'SLN-Ap-Ad-Gly ₇ -NHCH ₂] ₄ C	(53)	100
[6'SLN-Ap-Ad-AC ₂ -Gly ₅ -NHCH ₂] ₄ C	(54)	1000

Comparison Example 1

The compound of formula

{Neu5Acα2-6Galβ1-4GlcNAcβ1-NHCOCH₂NH-CO(CH₂)₄CO-(NHCH₂CO)₃-NHCH₂-}₄C,

which is known from Example 7 of WO 98/14215, does not form aggregates according to the invention, as has been demonstrated by the following methods:

1. In thin-layer chromatography only a single compound, the monomer, can be observed under the following conditions. Traces of aggregates are completely absent:

silica gel 60 TLC plates, catalogue no. 1.05724, Merck; eluant: *i*-PrOH / acetone / H₂O 4:3:2; observation: charring after immersion in 7% H₃PO₄.

2. The ^1H -NMR spectrum (Bruker 500 MHz, D_2O , 300 K) of the compound does not exhibit any line broadening that would be characteristic of glycopeptide aggregates.
3. Laser light-scattering experiments (Coulter Submicron Model N4MD, He-Ne laser, λ 632.8) on the compound in aqueous solution do not give any indication of the formation of aggregates.
4. Using gel permeation HPLC (TSK-4000 column, 0.2M NaCl), only one peak is observed, which corresponds to the molecular weight of the monomer.
5. The activity of the compound in the inhibition of influenza viruses (A/NIB/23/89M H1N1, A/NIB/44/90M H3N2, B/NIB/15/89M, FBI test) is comparable with that of 6'-SLN trisaccharide, whereas typical associated glycopeptides, such as, for example, the Gly₇ analogon) are more active by factors of ten.

It is therefore clear that the compound known from the prior art is fundamentally different from the compounds of the present invention. The demonstrated functional difference is based on the structural difference of the fragment K, which is not suitable for intermolecular association because the number of chain segments suitable for the formation of hydrogen bridges is too small.

Patent claims

1. Compound of the general formula (I)



wherein

X is an m-valent unit and

B are identical or different and denote K-R,
wherein

K is a bond or is $A^1-(A^2-A^3)_k$ -sp, wherein

A^1 is $(CH_2)_tY(CH_2)_u$, wherein

Y is $>C=O$, $>NH$, $-O-$, $-S-$ or a bond,

t is an integer from 0 to 6 and

u is an integer from 0 to 6,

A^2 is $-NHCO-$, $-CONH-$, $-OCONH-$ or $SCONH-$, or is $-CO-$,

A^3 is $(CH_2)_r$, $O(CH_2)_r$, $NH(CH_2)_r$, $S(CH_2)_r$ or $-(CHQ)-$, wherein

r is an integer from 1 to 6 and

Q is a substituted or unsubstituted alkyl or aryl group,

sp is a divalent spacer or a bond, and

k is an integer from 5 to 100, and

R is hydrogen; a ligand suitable for specific bonding to a receptor;
a marker molecule; or a catalytically active group; and

m is at least 2,

with the proviso that

- (1) in the compound at least one R is not hydrogen,
- (2) there are at least two K that are not a bond, and
- (3) X, B and m are so selected that an intermolecular association of the K in liquid phase by the formation of hydrogen bonds is possible, with formation of aggregates that present on the surface a plurality of R that are not hydrogen, and
- (4) the molar mass of the fragment $X(K)_m$ is less than 20,000.

2. Compound according to claim 1, wherein the molar mass of the fragment $X(K)_m$ is less than 4,000.

3. Compound according to either claim 1 or claim 2, wherein

- m is an integer from 2 to 4, and
- X is CH_{4-m} , NH_{3-m} , N^+H_{4-m} , $>\text{P}-$ (when $m = 3$), $>\text{P}^+<$ (when $m = 4$), $>\text{B}-$ (when $m = 3$), a linear atom group C_2H_{6-m} , $>\text{CH}(\text{CH}_2)_z\text{CH}<$, $>\text{C}=\text{C}<$, $>\text{N}-\text{N}<$, $>\text{N}(\text{CH}_2)_z\text{N}<$ wherein $z = 2 - 6$, when $m = 4$), a carbocyclic atom group C_6H_{6-m} , $\text{C}_6\text{H}_{12-m}$, or a heterocyclic atom group C_3N_3 (when $m = 3$), C_4N_2 (when $m = 4$).
4. Compound according to any one of claims 1 to 3, wherein there are at least 3 K.
 5. Compound according to any one of claims 1 to 4, wherein at least two R are not hydrogen.
 6. Compound according to any one of claims 1 to 4, wherein at least three R are not hydrogen.
 7. Compound according to any one of claims 1 to 6, wherein the ligand R is a mono- or oligo-saccharide, a peptide, a mono- or oligo-nucleotide or a nucleic base and their derivatives and mimetics.
 8. Compound according to claim 7, wherein the saccharide R is sialic acid, sialyl lactose, sialyl lactosamine, lactose, mannose, $\text{Gal}\alpha 1-3\text{Gal}$, $\text{Gal}\alpha 1-3(\text{Fuc}\alpha 1-2)\text{Gal}$, $\text{GalNAc}\alpha 1-3(\text{Fuc}\alpha 1-2)\text{Gal}$, $\text{Neu5Ac}\alpha 2-6\text{GalNAc}$, SiaLe^A , SiaLe^X , HSO_3Le^A , HSO_3Le^X , $\text{Gal}\alpha 1-3\text{Gal}\beta 1-4\text{GlcNAc}$, $\text{Gal}\alpha 1-3\text{Gal}\beta 1-4\text{Glc}$, $\text{HSO}_3\text{GlcA}\beta 1-3\text{Gal}\beta 1-4\text{GlcNAc}$, N-acetyl-lactosamine or polylactosamine, or wherein the saccharide is sialic acid benzyl glycoside, $\text{HSO}_3\text{GlcA}\beta 1-3\text{Gal}$, $\text{HSO}_3\text{GlcA}\beta 1-3\text{Gal}\beta 1-4\text{GlcNAc}\beta 1-3\text{Gal}\beta 1-4\text{Glc}$, $\text{GalNAc}\alpha$, $\text{GalNAc}\alpha 1-3(\text{Fuc}\alpha 1-2)\text{Gal}\beta 1-4\text{GlcNAc}$, $\text{Gal}\alpha 1-3(\text{Fuc}\alpha 1-2)\text{Gal}\beta 1-4\text{GlcNAc}$, $\text{HSO}_3(\text{Sia})\text{Le}^X$, $\text{HSO}_3(\text{Sia})\text{Le}^A$, Le^Y , $\text{GlcNAc}\beta 1-6(\text{GlcNAc}\beta 1-3)\text{Gal}\beta 1-4\text{Glc}$, $\text{GalNAc}\beta 1-4(\text{Neu5Ac}\alpha 2-3)\text{Gal}\beta 1-4\text{Glc}$, mannose-6-phosphate, $\text{GalNAc}\beta 1-4\text{GlcNAc}$, oligo-sialic acid, N-glycolylneuraminic acid, $\text{Gal}\alpha 1-4\text{Gal}\beta 1-4\text{Glc}$, $\text{Gal}\alpha 1-4\text{Gal}\beta 1-4\text{GlcNAc}$.
 9. Compound according to any one of claims 1 to 8, wherein

m is an integer from 2 to 4,

X is CH_{4-m} ,

A^1 is CH_2 ,

A^2 is NHCO ,

A^3 is CH_2 ,

k is 8,

sp is $(\text{CH}_2)_3\text{CONHCH}_2\text{CONHC}_6\text{H}_4-4-\text{CH}_2\text{O}-$ and

17. Preparation, comprising a compound as defined in any one of claims 1 to 9 or an aggregate as defined in any one of claims 10 to 12, for use in therapeutic or diagnostic procedures.

18. Preparation according to claim 17 against inflammation, viral and bacterial infections, influenza viruses, selectin-mediated inflammatory processes, tumour metastases, or in the neutralisation of antibodies in autoimmune disorders and transplants.
19. Use of a compound as defined in any one of claims 1 to 9 or of an aggregate as defined in any one of claims 10 to 12 in the preparation of a medicament against inflammation, viral and bacterial infections, influenza viruses, selectin-mediated inflammatory processes, tumour metastases, or in the neutralisation of antibodies in autoimmune disorders and transplants.
20. Use of a compound as defined in any one of claims 1 to 9 or of an aggregate as defined in any one of claims 10 to 12 in the preparation of functionalised molecular surfaces.
21. Use of a compound as defined in any one of claims 1 to 9 or of an aggregate as defined in any one of claims 10 to 12 in an analytical procedure.
22. Use according to claim 21 in a diagnostic procedure.
23. Compound of the general formula (III),



wherein

X is an m-valent unit and

B are identical or different and denote K-H,
wherein

K is $A^1-(A^2-A^3)_k$ -sp,

wherein

A^1 is $(CH_2)_tY(CH_2)_u$, wherein

Y is $>C=O$, $>NH$, $-O-$, $-S-$ or a bond,

t is an integer from 0 to 6 and

u is an integer from 0 to 6,

A^2 is $-NHCO-$, $-CONH-$, $-OCONH-$ or $SCONH-$, or is $-CO-$,

A^3 is $(CH_2)_r$, $O(CH_2)_r$, $NH(CH_2)_r$, $S(CH_2)_r$, or $-(CHQ)-$, wherein

r is an integer from 1 to 6 and

Q is a substituted or unsubstituted alkyl or aryl group,

sp is a divalent spacer or a bond, and

k is an integer from 5 to 100, and

m is at least 2,

with the proviso that

- (1) X, B and m are so selected that an intermolecular association of the K in liquid phase is possible, especially under aqueous conditions, by the formation of hydrogen bonds, with formation of aggregates, and
- (2) the molar mass of the fragment $X(K)_m$ is less than 20,000, especially less than 4000.

24. Use of a compound of the general formula (III) according to either one of claims 22 and 23 in the modification of an aggregate as defined in either one of claims 10 and 11.

Abstract

Compound of the general formula (I)



wherein

X is an m-valent unit and

B are identical or different and denote K-R,

wherein

K is a bond or is $A^1-(A^2-A^3)_k-sp$, wherein

A^1 is $(CH_2)_tY(CH_2)_u$, wherein

Y is $>C=O$, $>NH$, $-O-$, $-S-$ or a bond,

t is an integer from 0 to 6 and

u is an integer from 0 to 6,

A^2 is $-NHCO-$, $-CONH-$, $-OCONH-$ or $SCONH-$, or is $-CO-$,

A^3 is $(CH_2)_r$, $O(CH_2)_r$, $NH(CH_2)_r$, $S(CH_2)_r$ or $-(CHQ)-$, wherein

r is an integer from 1 to 6 and

Q is a substituted or unsubstituted alkyl or aryl group,

sp is a divalent spacer or a bond, and

k is an integer from 5 to 100, and


R is hydrogen; a ligand suitable for specific bonding to a receptor; a marker molecule; or a catalytically active group; and

m is at least 2,

with the proviso that

- (1) in the compound at least one R is not hydrogen,
- (2) there are at least two K that are not a bond, and
- (3) X, B and m are so selected that an intermolecular association of the K in liquid phase by the formation of hydrogen bonds is possible, with formation of aggregates that present on the surface a plurality of R that are not hydrogen, and
- (4) the molar mass of the fragment $X(K)_m$ is less than 20,000.


Figure 1



Elution profiles of aggregates $\{[\text{Neu5Ac-Gab-AC}_m\text{-Ad-Gly}_5\text{-NHCH}_2\text{-}]_4\text{C}\}_x$,
HPLC, TSK-4000, 0.2M NaCl


2/3

Figure 2



Relative particle size distribution of aggregate
 $\{[\text{Neu5Ac-Gab-Ad-AC}_3\text{-Gly}_5\text{-NHCH}_2\text{-I}_4\text{C}]\}_x$, 20°C H₂O

Figure 3



Influence of temperature and of the presence of urea on the particle size of aggregate $\{[\text{Neu5Ac-Gab-Ad-Gly}_7\text{-NHCH}_2]_4\text{C}\}_x$

DECLARATION AND POWER OF ATTORNEY FOR PATENT APPLICATION

Attorney Docket No. 9286-7

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am an original, first and joint inventor of the subject matter which is claimed and for which a patent is sought on the invention entitled ***Intermolecularly Associating Compounds, and Aggregates Comprising Them,***

the specification of which

☐ is attached hereto

OR

☒ was filed on June 30, 2000 as United States Application No. _____ or PCT International Application Number PCT/EP00/06139 and as amended on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37 Code of Federal Regulations, §1.56, including material information that became available between the filing date of the prior application and the National or PCT International filing date of the continuation-in-part application, if applicable.

I hereby claim foreign priority benefits under Title 35, United States Code, § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT International application which designated at least one country other than the United States of America, listed below and have also identified below any foreign application for patent or inventor's certificate, or of any PCT International application having a filing date before that of the application on which priority is claimed.

199 30 177.8	Germany	June 30, 1999	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Number	Country	MM/DD/YYYY Filed	Priority Claimed
			<input type="checkbox"/> Yes <input type="checkbox"/> No
Number	Country	MM/DD/YYYY Filed	Priority Claimed
			<input type="checkbox"/> Yes <input type="checkbox"/> No
Number	Country	MM/DD/YYYY Filed	Priority Claimed

I hereby claim the benefit under Title 35, United States Code, § 119(e) of any United States provisional application(s) listed below.

Application Number(s)	Filing Date (MM/DD/YYYY)
Application Number(s)	Filing Date (MM/DD/YYYY)

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) or § 365(c) of any PCT international application designating the United States of America, listed below.

PCT/EP00/06139	June 30, 2000	Published
Appln. Serial No.	Filing Date	Status Patented/Pending/Abandoned
Appln. Serial No.	Filing Date	Status Patented/Pending/Abandoned
Appln. Serial No.	Filing Date	Status Patented/Pending/Abandoned

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following registered attorney(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. I also appoint the following registered attorney(s) to represent me before all competent International Authorities in connection with any and all international applications filed by me with an appropriate receiving office claiming priority to the U.S. application. I also appoint the following registered attorney(s) to make or receive payment on my behalf in connection with the filing of such international applications.

300

Full name of third inventor: Alexander Alexandrovich Chinarev

Inventor's

Signature: A. ChinarevDate: 29/03/2002

Residence:

Moskow, Russia RUX

Citizenship:

Russia


Mailing Address:

121059 Moskow
Berezhkovskaya naberezhnaya 2, kv. 53
Russia

400

Full name of fourth inventor: Maria Alexandravona Dicusar

Inventor's

Signature: 

Date: 01 April, 2002

Residence:

Moskow, Russia *RUX*

Citizenship:

Russia

Mailing Address:

127238 Moskow
3th Nizhnelichoborsky proezd 2/1, kv. 19
Russia

